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ABSTRACT 
 Pancreatic beta cells sense fluctuations in circulating nutrients and adjust 
the rate of insulin secretion to maintain glucose homeostasis. Mitochondria 
integrate changes in nutrient flux to the generation of signals that modulate 
insulin secretion via oxidative phosphorylation. Type 2 Diabetes (T2D) is 
characterized by beta cell mitochondrial dysfunction and impairment of insulin 
secretion. Early stage progression of this disease in obese and pre-diabetic 
subjects is characterized by basal hypersecretion of insulin and increased insulin 
resistance in peripheral tissues including muscle, liver and adipose tissue. 
Whether basal hypersecretion of insulin or insulin resistance is the primary defect 
in T2D progression is still debated. The molecular mechanism underlying basal 
insulin hypersecretion and how it may lead to beta cell failure are not understood. 
Herein, we optimize a model of glucolipotoxicity that results in increased basal 
and reduced stimulated insulin secretion response. Furthermore, we show that 
pancreatic islets exposed to excess nutrients in vitro or isolated from high fat diet 
fed animals, have a decreased bioenergetic efficiency, which is characterized by 
	 ix 
increased mitochondrial proton leak. Leak represents the fraction of oxygen 
consumed that is not coupled to ATP production. We show that leak is sufficient 
to induce insulin secretion at basal glucose levels and that nutrient-induced 
insulin secretion at basal glucose is leak-dependent. Finally, we identify the 
mitochondrial permeability transition pore (PTP) as the source of the leak. Our 
findings suggest the PTP may be a potential therapeutic target to prevent/delay 
the onset of hyperinsulinemia in pre-diabetic subjects.  
	 x 
TABLE OF CONTENTS 
 
DEDICATION ................................................................................................................... iv	
ACKNOWLEDGMENTS .................................................................................................. v	
TABLE OF CONTENTS .................................................................................................... x	
LIST OF FIGURES ......................................................................................................... xiv	
LIST OF ABBREVIATIONS .......................................................................................... xvi	
CHAPTER ONE: General Introduction .............................................................................. 1	
Diabetes Pathology, Prevalence ...................................................................................... 1	
Pancreatic β-cell Physiology ........................................................................................... 2	
How do Pancreatic beta Cells Secrete Insulin? ............................................................... 3	
1) Glucose Entry ......................................................................................................... 3	
2) Glucose Oxidation .................................................................................................. 4	
3) Membrane Depolarization and Exocytosis ............................................................. 4	
Depolarization & Voltage-gated Calcium Channels ................................................... 5	
Exocytosis of Insulin................................................................................................... 6	
Β-cell Dysfunction in Diabetes Progression ................................................................... 7	
Evidence for Hyperinsulinemia as Primary Defect in Diabetes ..................................... 8	
Regulation of Basal Insulin Secretion ........................................................................... 10	
The Role of Excess FFA in beta Cell Dysfunction in Pre-diabetes and T2D ............... 12	
Lipids and Insulin Secretion .................................................................................. 12	
	 xi 
Development of the Lipotoxicity Hypothesis ........................................................... 13	
Saturated vs. Unsaturated Fatty Acids ...................................................................... 14	
Role of Mitochondria in Lipid-induced beta Cell Dysfunction .................................... 16	
Mechansims for beta Cell Bioenergetic Inefficiency and its Relevance for T2D and 
beta Cell Dysfunction Induced by Lipids ..................................................................... 18	
Overexpression Studies ............................................................................................. 19	
Knockout Studies ...................................................................................................... 21	
Evidence Against UCP2 Leak Role .......................................................................... 22	
Permeability Transition Pore as a Physiological Leak Mechanism .............................. 23	
Identification/Characterization/Regulation ............................................................... 23	
Structure of the Permeability Transition Pore .......................................................... 25	
Pathophysiological Roles of PTP ............................................................................. 29	
Physiological Role of PTP ........................................................................................ 30	
CHAPTER TWO: Methods .............................................................................................. 33	
Cell Culture and Reagents ............................................................................................ 33	
Animals ......................................................................................................................... 33	
Genotyping .................................................................................................................... 34	
Islet Isolation ................................................................................................................. 34	
Insulin Secretion Assay- INS1 ...................................................................................... 35	
Insulin Secretion Assay-Islets ....................................................................................... 36	
Insulin Measurements ................................................................................................... 36	
Western Blotting ........................................................................................................... 37	
	 xii 
Preparation of Fatty Acids ............................................................................................ 38	
Palmitate-BSA .......................................................................................................... 38	
BSA Control ............................................................................................................. 38	
Oleate-Palmitate BSA ............................................................................................... 39	
Oleate-FBS ................................................................................................................ 39	
Respirometry/O2 Consumption ..................................................................................... 40	
Quantification of Lipid Content .................................................................................... 40	
Reactive Oxygen Species Measurements ..................................................................... 41	
CHAPTER THREE: Optimization of a β-cell Model of Glucolipotoxicity ..................... 42	
Introduction ................................................................................................................... 43	
Results ........................................................................................................................... 44	
Optimization of Palmitate Lipotoxicity Model ......................................................... 44	
Discussion ..................................................................................................................... 49	
Technical Considerations .......................................................................................... 49	
Glucotoxicity is a Prerequisite for Detrimental Effects of Excess Lipids ................ 50	
Serum is Protective from Glucotoxicity ................................................................... 51	
CHAPTER FOUR: Cyclophilin D-dependent Mitochondrial Proton Leak Regulates 
Insulin Secretion at Basal Glucose ................................................................................... 61	
Introduction ................................................................................................................... 62	
Results ........................................................................................................................... 64	
Mitochondrial Proton Leak Stimulates Basal Insulin Secretion in Islets ................. 64	
	 xiii 
Reactive Oxygen species Increase Mitochondrial Proton Leak and Basal Insulin 
Secretion in Islets ...................................................................................................... 66	
Amino-acid and Fatty Acid Stimulation of Insulin Secretion at Basal Glucose is 
ROS-dependent. ........................................................................................................ 67	
The Mitochondrial Permeability Transition Pore Regulates Proton Leak and Insulin 
Secretion in Islets ...................................................................................................... 68	
Role of Cyclophilin D on Leak, Basal and Glucose Stimulated Insulin Secretion ... 70	
The mitochondrial permeability transition pore regulates proton leak and insulin 
secretion in islets from high fat-fed mice ................................................................. 71	
Proton leak induced insulin secretion requires generation of mitochondrial GTP ... 71	
Discussion ..................................................................................................................... 73	
CHAPTER FIVE: General Discussion ........................................................................ 99	
Glucolipotoxicty: Challenges, Considerations, and Implications for β-cell Function 100	
β-cell Specific Physiological Considerations ......................................................... 102	
Proton Leak Regulation of Insulin Secretion .............................................................. 103	
Role of Cyclophilin D in Metabolic Diseases ............................................................. 105	
Pharmacological Implications of PTP Inhibition ........................................................ 107	
Conclusions and Future Directions ............................................................................. 110	
BIBLIOGRAPHY ........................................................................................................... 111	
CURRICULUM VITAE ................................................................................................. 137	
 
 
	 xiv 
LIST OF FIGURES 
Figure 1.1. Conventional Model for Progression of T2D. ................................................ 31	
Figure 1.2. Alternative Model for T2D Progression: Basal Hyperinsulinemia Leads to 
T2D. .......................................................................................................................... 32	
Figure 3.1.  Optimization of Palmitate Lipotoxicity Model. ............................................ 53	
Figure 3.2.  Comparison of Different Models of Excess Nutrients on beta cell Insulin 
Secretion. .................................................................................................................. 54	
Figure 3.3.  Influence of Serum reduction or addition of FA-free BSA on insulin secretion
................................................................................................................................... 55	
Figure 3.4 Reduction of Serum Depletes Intracellular Lipid ............................................ 57	
Figure 3.5. Oleate GLT Model-Lipotoxicity Increases Basal Insulin Secretion and 
Impairs GSIS ............................................................................................................. 59	
Figure 4.1. Mitochondrial Proton Leak Stimulates Basal Insulin Secretion in Islets. ...... 78	
Figure 4.2. Reactive Oxygen Species Increase Mitochondrial Proton Leak and Basal 
Insulin Secretion in Islets. ......................................................................................... 80	
Figure 4.3. Amino-acid and Fatty Acid Stimulation of Insulin Secretion at Basal Glucose 
is ROS-dependent. .................................................................................................... 82	
Figure 4.4. The Mitochondrial Permeability Transition Pore Regulates Proton Leak and 
Insulin Secretion in Islets. ......................................................................................... 84	
Figure 4.5. Cyclophilin D Deficient Islets Display Lower Mitochondrial Proton Leak and 
Insulin Secretion at Basal Glucose ........................................................................... 86	
	 xv 
Fig 4.6.  The Mitochondrial Permeability Transition Pore Regulates Proton Leak and 
Insulin Secretion in HFD Mouse Islets ..................................................................... 88	
Figure 4.7. Proton leak induced insulin secretion requires generation of mitochondrial 
GTP ........................................................................................................................... 91	
Figure 4.8. Mechanism of Elevated Insulin Secretion at Basal Glucose Concentrations. 93	
Supplementary Figure 4.1. Mitochondrial bioenergetics and insulin secretion in mouse 
islets treated with uncouplers. ................................................................................... 94	
Supplementary Figure 4.2. Ablation of CypD does not reduce insulin secretion or leak 
under stimulatory glucose levels. .............................................................................. 96	
Supplementary Figure 4.3. Mitchondrial GTP increases both basal and glucose stimulated 
insulin secretion. ....................................................................................................... 98	
 
 
 
  
	 xvi 
LIST OF ABBREVIATIONS 
ADP ................................................................................... Adenosine diphosphate 
ANT ........................................................................ Adenine nucleotide transporter 
ATP .................................................................................... Adenosine triphosphate 
CPT1 ................................................................... Carnitine Palmitoyl Transferase I 
CsA .................................................................................................... Cyclosporin A 
CypD ................................................................................................... Cyclophilin D 
DAG ................................................................................................... Diacylglycerol 
DNP .................................................................................................... Dinitrophenol 
DZ ............................................................................................................ Diazoxide 
ER ...................................................................................... Endoplasmic Reticulum 
ETC ................................................................................. Electron Transport Chain 
FA ............................................................................................................ Fatty Acid 
FAO ......................................................................................... Fatty Acid Oxidation 
FBG ...................................................................................... Fasting blood glucose 
FBS ........................................................................................... Fetal bovine serum 
FCCP ................................. Carbonyl Cyanide P-trifluoromethoxyphenylhydrazone 
FFA .................................................................................................. Free Fatty Acid 
G3P ....................................................................................... Glycerol 3 Phosphate 
G6P ....................................................................................... Glucose 6-phosphate 
GK ....................................................................................................... Glucokinase 
GL ......................................................................................................... Glycerolipid 
	 xvii 
GLT ................................................................................................ Glucolipotoxicity 
GLUT ....................................................................................... Glucose transporter 
GPR40 ..................................................................... G-protein coupled receptor 40 
GSIS ............................................................. Glucose-Stimulated Insulin Secretion 
HI ................................................................................................. Hyperinsulinemia 
IGT ................................................................................ Impaired glucose tolerance 
IR ................................................................................................ Insulin Resistance 
KATP ................................................................................. ATP-sensitive K+ channel 
KCl ............................................................................................. Potassium chloride 
KREBS ................................................................. Krebs-ringer Bicarbonate Buffer 
LC ......................................................................................................... Long-Chain 
MAG ............................................................................................ Monoacylglycerol 
mGTP .......................................................... Mitochondrial guanosine triphosphate 
mtDNA ....................................................................................... mitochondrial DNA 
NN414 ................................................................................................. Tifenazoxide 
NNT ..................................................... Nicotinamide nucleotide transhydrogenase 
OCR ................................................................................ Oxygen consumption rate 
OP ................................................................................................ Oleate/Palmitate 
OMM ...................................................................... Outer mitochondrial membrane 
OCSP ......................................................... Oligomycin sensitivity conferral protein 
PDH ................................................................................. Pyruvate dehydrogenase 
PEP ...................................................................................... Phosphoenolpyruvate 
	 xviii 
PEPCK ......................................................... Phosphoenolpyruvate carboxykinase 
PK .................................................................................................. Pyruvate Kinase 
PFK ........................................................................................ Phosphofructokinase 
PPIF .................................................................. Peptidyl-prolyl cis-trans isomerase 
PTP .............................................................................. Permeability transition pore 
ROS ................................................................................ Reactive Oxygen Species 
SNARE .. Soluble N-ethylmaleimide-sensitive Factor Attachment Protein Receptor 
SUR1 ................................................................................. Sulfonyl urea receptor 1 
T2D ................................................................................................ Type 2 Diabetes 
TAG .................................................................................................. Triacylglycerol 
TCA ............................................................................................. Tricarboxylic acid 
TG ......................................................................................................... Triglyceride 
UCP ........................................................................................... Uncoupling protein 
VDAC ................................................................. Voltage-Dependent Ca2+ Channel 
ZDF .......................................................................................... Zucker diabetic fatty 
		 1 
CHAPTER ONE: General Introduction 
 
Diabetes Pathology, Prevalence  
 
Type 2 Diabetes (T2D) is a chronic metabolic disease characterized by 
hyperglycemia (Golay & Ybarra, 2005). T2D increases the risk of cardiovascular 
disease and stroke and leads to neuropathy, retinopathy and kidney failure 
(Khalil, 2016; Sheetz & King, 2002). The rise in T2D prevalence both in the US 
and globally is increasing at an alarming rate (Guariguata et al., 2014; Roglic, 
2016). The most recent International Diabetes Federation (IDF) data reports the 
global prevalence of diabetes at 8.8% in 2015 and is expected to rise to 10.4% 
by 2040 (Ogurtsova et al., 2017). The escalation in the incidence of diabetes 
creates a substantial economic burden due to increases in diabetes related 
medical care costs (Caspersen, Thomas, Boseman, Beckles, & Albright, 2012; 
Ogurtsova et al., 2017). This, in conjunction with a sharp rise in the prevalence of 
obesity, has created a need for extensive research to address the mechanisms 
involved in the progression of T2D. Diabetes is associated with development of 
insulin resistance and beta failure (Kasuga, 2006). The vast majority of research 
was focused on insulin resistance since this was thought to be the driver of 
diabetes. It has recently been shown, however, that the progression from pre-
diabetes to diabetes may result from beta cell dysfunction (Page & Johnson, 
2018). A clear understanding of the basic physiology of the pancreatic beta cell is 
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essential to elucidate the pathophysiology involved in diabetes development, 
leading to better therapeutics to prevent or delay progression of this epidemic 
disease.  
 
Pancreatic β-cell Physiology 
 
The pancreas is a critical organ that plays an important role in the 
digestive and endocrine systems. It has an endocrine and exocrine component. 
The exocrine pancreas produces digestive juices that flow from the pancreatic 
duct to the duodenum of the small intestine to enable digestion of food. The 
endocrine pancreas is composed of the Islets of Langerhans, which include β-
cells, α-cells, δ-cells, and γ-cells. These cells secrete insulin, glucagon, 
somatostatin, and pancreatic polypeptide, respectively (Dolenšek, Rupnik, & 
Stožer, 2015). The secretion of glucagon by the α-cells and insulin by the β-cells 
is fundamental to proper blood glucose regulation, as they work inversely to each 
other to either increase or decrease blood glucose (Röder, Wu, Liu, & Han, 
2016). Under fasting conditions, pancreatic α-cells stimulate the secretion of 
glucagon, promoting the breakdown of glycogen to glucose in the liver, which 
raises blood sugar back to normal. Conversely, pancreatic β-cells secrete insulin 
after ingestion of a meal to increase glucose uptake from the blood and into the 
peripheral tissues, stimulating glycogen formation in the liver, and serving to 
lower the concentration of blood glucose back to normal. 	
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How do Pancreatic beta Cells Secrete Insulin? 
 
Pancreatic beta-cells sense nutrients to maintain blood glucose 
homeostasis by secreting insulin. The canonical pathway of the pancreatic beta-
cell insulin secretion is also referred to as glucose-stimulated insulin secretion 
(GSIS). It has three defined steps:  
 
1) Glucose Entry 
Glucose enters the beta cell through GLUT2 transporters via facilitated 
diffusion and is phosphorylated to produce glucose-6-phosphate via the rate-
limiting enzyme glucokinase (Matschinsky, Glaser, & Magnuson, 1998). Rodents 
primarily express the high Km (11.2mM) GLUT2 transporters, while human islets 
and beta cells have been shown to express GLUT1 (Km 6.9mM) and GLUT3 
(Km 1.3mM)(Gould & Holman, 1993; Henquin, Dufrane, & Nenquin, 2006).  
 
While the expression of the GLUT transporters in humans and rodents are 
disparate, its has been shown that expression and influence of glucokinase is 
similar making it a central control point for GSIS(De Vos et al., 1995; 
Matschinsky et al., 1998). Glucokinase has a rate-limiting step in glucose 
metabolism (Z. Fu, Gilbert, & Liu, 2013). Unlike its isozyme, Hexokinase, 
glucokinase has 2 unique features: a lower affinity for glucose (Km 6mmol/L), 
which places it in an ideal physiological range (4-10mmol/L), as well as a lack of 
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product inhibition, enabling it to serves as a glucose sensor (Z. Fu et al., 2013; 
Matschinsky, 1996). 
 
2) Glucose Oxidation 
Glucose is further metabolized to pyruvate via glycolysis and enters the 
TCA cycle in the mitochondria to fuel the synthesis of ATP by oxidative 
phosphorylation. The increase in cellular ATP/ADP ratio leads to the closure of 
the ATP-sensitive potassium channels, which results in the depolarization of the 
plasma membrane (F. M. Ashcroft, 2006; F. M. Ashcroft, Harrison, & Ashcroft, 
1984). Upon depolarization, voltage-gated calcium channels are opened, leading 
to insulin secretion (Wollheim & Sharp, 1981). Mitochondrial oxidative function is 
central to this process, as mitochondrial defects were shown to disturb normal 
beta-cell function (Anello et al., 2005; Maechler & Wollheim, 2001; Stiles & 
Shirihai, 2012). 
 
3) Membrane Depolarization and Exocytosis  
The KATP channel serves as a link that senses the increase in glucose via 
an increase in the ATP/ADP ratio and the subsequent electrical excitation of the 
cell signaling the release of insulin. The KATP channel is open under low glucose 
conditions, allowing efflux of K down its gradient and keeping the cell in a 
hyperpolarized state. After a meal, under high glucose conditions, the increase in 
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the ATP/ADP ratio leads to the closure of the KATP channel consequently leading 
to the depolarization of the cell and secretion of insulin. Gain of function or loss of 
function mutations in this channel may result in diabetes or hyperinsulinism. Also, 
the SUR1 protein, a regulatory component of the KATP channel which senses 
changes in ATP and ADP, is the target of sulfonylurea drugs that stimulate 
insulin secretion by causing closure of the KATP channel thereby improving 
glycemic control(K. Bennett, James, & Hussain, 2010). 
 
Depolarization & Voltage-gated Calcium Channels 		
The beta cell is electrically inactive at a resting membrane potential of 
approximately -70mV when the concentrations of glucose are less than 5mM. As 
the glucose concentration increases, the cell is depolarized and action potentials 
start to fire (threshold of -55mV to -50mv) in an oscillatory manner in the range of 
6-17mM of glucose (Rorsman, Braun, & Zhang, 2012). With the advent of the 
patch-clamp method, it was possible to characterize the different ion channels 
involved in the electrically excitable beta cell. It was found that the membrane 
resistance increases as a result of the closure of the KATP channel leading to the 
opening of the T-type Ca2+ channels, which respond to a low threshold potential 
(activated by low change in voltage, -60mV). This subsequently activates the Na+ 
and L-type Ca2+ channels that correspond to the fast but brief upward stroke of 
the action potential. The activation of the P/Q Ca2+ channels contributes to the 
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peak of the action potential and triggers exocytosis of insulin vesicles. 
Repolarization of the action potential is a result of the activation of the high 
conductance K+ channels (BK), which sense the increase in intracellular calcium 
and open, releasing the positively charged potassium ions thereby helping to 
reset the cells membrane potential(Rorsman et al., 2012). 	
Exocytosis of Insulin 
 
Insulin secretion occurs in a regulated biphasic manner. The first phase of 
secretion is termed the readily releasable pool as it involves predocked granules 
that respond to the KCl and non-nutrient secretagogues (Gembal, Gilon, & 
Henquin, 1992; Z. Wang & Thurmond, 2009). The second phase of insulin 
release, however, responds to the change in glucose concentration and has a 
much higher impact, releasing 4-50 granules per cell per minute over a long 
period of time. The second phase of insulin release involves a rearrangement of 
the F-actin filaments, allowing the insulin granules to fuse with the plasma 
membrane in a SNARE dependent manner in which VAMP2, a v-SNARE, 
interacts with the syntaxins on the plasma membranes (t-SNAREs) in order to 
mediate the docking, fusion, and release of the insulin granules (Z. Wang & 
Thurmond, 2009). Impairment in this regulated process of both first and second 
phase has been associated with Type 2 Diabetic patients. This is especially 
important in the second phase of insulin release as the first phase only accounts 
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for approximately 1% of total granule insulin release, while the second phase is 
sustained for longer, and accounts for a larger total magnitude (Barg, Eliasson, 
Renström, & Rorsman, 2002). As insulin granules are synthesized, they are 
stored for days awaiting a signal for release. During that time the older, aged 
granules are subjected to degradation.  It has recently been shown that the 
secretion of insulin granules occurs in an age-dependent manner. Younger 
insulin granules (less than 48 hours) are more likely to be released first (Hou et 
al., 2012; Michael, Xiong, Geng, Drain, & Chow, 2007).  
 
Β-cell Dysfunction in Diabetes Progression 
 
Progression of diabetes is recognized to be a consequence of increased 
in insulin resistance and impairment of beta-cell function (Kahn, 2003). A strong 
association between obesity and development of T2D has been established 
(Golay & Ybarra, 2005; N. T. Nguyen, Nguyen, Lane, & Wang, 2011a). The 
majority of diabetics are obese, while the opposite does not hold true. This 
observation raised the question of investigating the relationship of fat 
accumulation to changes in insulin sensitivity. It has been shown that 
accumulation of visceral fat is the primary correlate to insulin sensitivity (Cnop et 
al., 2002; Kahn, 2003). In the progression of individuals from normal lean 
subjects, to obese individuals, to development of impaired glucose tolerance and 
ultimately diabetes, there is a concomitant rise in the levels of basal insulin 
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secretion from pancreatic beta cells (Pories & Dohm, 2012). Indeed, one of the 
first changes is hypersecretion of insulin in the fasting/basal state observed in the 
prediabetic obese, hyper-lipidemic state. Hypersecretion of insulin can indeed 
lead to insulin resistance either by downregulation or impaired sensitivity of 
insulin receptors in the peripheral tissues (Soman & DeFronzo, 1980). Insulin not 
only regulates blood glucose levels, but is also an anabolic hormone, thereby 
promoting fat storage leading to weight gain (Dimitriadis, Mitrou, Lambadiari, 
Maratou, & Raptis, 2011). Increased circulating lipids further exacerbate beta cell 
function by promoting basal hyperinsulinemia. Beta cell failure ultimately ensues 
when beta cells can no longer compensate for changes in peripheral tissue 
insulin sensitivity (Prentki & Nolan, 2006).  
 
Evidence for Hyperinsulinemia as Primary Defect in Diabetes 
 
Hyperinsulinemia (HI) is thought to represent a compensatory response to 
peripheral insulin resistance. Beta cell compensation ultimately leads to beta cell 
failure, in which beta cells do not secrete a sufficient amount of insulin in 
response to an acute nutrient challenge(Nolan, Leahy, Delghingaro-Augusto, 
Moibi, Soni, Peyot, et al., 2006a; Prentki & Nolan, 2006). During diabetes 
progression, there is a reduction in beta cell mass and/or differentiation of beta 
cells leading to functional loss and insulin dependence (Weir & Bonner-Weir, 
2004). However, there is no conclusive evidence to support this hypothesis. 
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Multiple knockout models of insulin resistance have failed to manifest 
development of HI (Blüher et al., 2002; Brüning et al., 1998; Okamoto et al., 
2004). While it is true that a hyperbolic relationship between insulin sensitivity 
and insulin secretion exists, evidence indicates that hypersecretion of insulin may 
be the initial defect in progression of T2D(Corkey, 2012a; Retnakaran et al., 
2008). Multiple modes of chronic exposure to HI such as insulin infusion in 
humans, hyperglycemic clamps or transgenic animal models, demonstrate 
development of peripheral insulin resistance(P. D. Miles et al., 1998; Rizza, 
Mandarino, Genest, Baker, & Gerich, 1985; Shanik et al., 2008). Inhibition of 
insulin secretion with KATP channel agonists such as diazoxide and NN414 
improves insulin sensitivity in both human and animal studies further reinforcing 
this hypothesis(Alemzadeh, Fledelius, Bodvarsdottir, & Sturis, 2004; Alemzadeh, 
Langley, Upchurch, Smith, & Slonim, 1998; Carr, Brand, Bodvarsdottir, Hansen, 
& Sturis, 2003; Zdravkovic, Kruse, Rost, Møss, & Kecskes, 2007; Zdravkovic et 
al., 2005). Additionally, an etiologic role for HI has been shown in certain ethnic 
groups such as African Americans and Pima Indians which have a higher 
susceptibility for development of T2D that is unaccounted for by insulin 
resistance(Aronoff, Bennett, Gorden, Rushforth, & Miller, 1977; Arslanian, Saad, 
Lewy, Danadian, & Janosky, 2002; Weyer, Hanson, Tataranni, Bogardus, & 
Pratley, 2000). Remission of T2D post roux-en-y gastric bypass surgery in which 
HI is normalized independent of peripheral insulin resistance or weight loss is yet 
another interesting correlation suggesting a need to further dissect mechanisms 
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of HI(Camastra et al., 2011; Reed et al., 2011). In fact, prevention of fasting 
hyperinsulinemia by ablation of pancreatic beta cell specific insulin gene Ins1 is 
protective from diet-induced obesity (Mehran et al., 2012). It is currently unknown 
what mechanisms drive the hypersecretion of insulin in the beta cell. Thus, 
understanding mechanisms of basal hyperinsulinemia is critical and could 
indicate an early point of intervention at the pre-diabetic state to reverse 
development of T2D and prevent beta cell failure.  
 
Regulation of Basal Insulin Secretion 
 
Very little research has investigated the mechanisms underlying 
hypersecretion of insulin in the basal state. Boden and colleagues explored the 
possibility that basal FFAs potentiate basal insulin secretion by acutely lowering 
FFAs via administration of nicotinic acid, which prevents TG lipolysis by adipose 
tissues (Boden, Chen, & Iqbal, 1998) (Kamanna & Kashyap, 2008). This results 
in 25-33% reduction in basal secretion rate. This is contradictory to what is 
observed during fasting, when fatty acids are markedly high and insulin secretion 
is at its lowest. Evidence suggests that this may be due to signals that may 
influence the threshold required to activate calcium channels (Erion, Berdan, 
Burritt, Corkey, & Deeney, 2015). It is noteworthy to mention that glucose 
stimulation of insulin secretion in the fasted stated necessitates presence of free 
fatty acids (Stein et al., 1996). 
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Treatment of islets with oleate increased insulin secretion at basal glucose 
(Erion et al., 2015) and was shown to have a marked reduction in Glucose-6-
phosphate content, as a result of increased PFK activity. This is thought to occur 
from increased PFK expression (Clarke, 1994; Roche et al., 1997) or due to a 
shift of increased glucose utilization from glucokinase to hexokinase (Liang, 
Buettger, Berner, & Matschinsky, 1997), since increased conversion of LC-CoA 
to malonyl Co-A inhibits beta-oxidation through CPT-I (Brun et al., 1996; S. Chen 
et al., 1994). Triacsin C, a fatty acyl Co-A synthetase inhibitor, restored G6P 
content, prevented the oleate induced increase in PFK activity, and reduced 
basal insulin secretion, implicating a signaling role for LC-CoA (Y. Q. Liu, 
Tornheim, & Leahy, 1998). 
 
Monoglycerides were also shown to acutely stimulate basal insulin 
secretion via increased ROS production, without altering intracellular calcium or 
oxygen consumption (Saadeh et al., 2012). This occurred in a KATP independent 
manner, as treatment with diazoxide blunted GSIS, but had no effect on basal. 
Hence, monoglycerides may function as an in vitro tool to examine mechanisms 
of insulin secretion under basal glucose conditions. 
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The Role of Excess FFA in beta Cell Dysfunction in Pre-diabetes and T2D  
Lipids and Insulin Secretion 
 
Observations from early studies of intravenous lipid infusion in dogs 
indicated that elevated levels of plasma free fatty acids stimulate insulin secretion 
(Crespin, Greenough, & Steinberg, 1969; Madison, Seyffert, Unger, & Barker, 
1968) To establish a direct effect on the pancreas, Crespin et al directly infused 
sodium salts of oleic, linoleic, lauric, or palmitic acid into pancreatic arteries of 
dogs at physiological concentrations which equipotently stimulated insulin 
secretion without altering peripheral FFA levels (Crespin, Greenough, & 
Steinberg, 1973). The high oxidation rates fatty of palmitate and oleate revealed 
them to be important fuels for pancreatic beta cells in the fasting state, although 
no strong effect on insulin secretion is observed (Berne, 1975).  
 
Fatty acids acutely amplify insulin secretion but chronically are detrimental 
to beta cells function. High fat diet mice were shown to have reduced glucose 
stimulated insulin secretion and reduction in pro-insulin mRNA levels (Capito, 
Hansen, Hedeskov, Islin, & Thams, 1992). Correspondingly, chronic incubation 
with fatty acids was shown to inhibit GSIS, an effect that was prevented by 
inhibition of fatty acid oxidation (Elks, 1993) (Y. P. Zhou & Grill, 1994). It is well 
established that there is an increased level of circulating lipids in the pre-diabetic 
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obese state (Paolisso, Tataranni, et al., 1995b) (Jensen, Haymond, Rizza, Cryer, 
& Miles, 1989) 
 
Development of the Lipotoxicity Hypothesis 
 
Unger first developed the concept of lipotoxicity in the early 1990’s (Unger, 
1995). This idea followed evidence from defects produced by FFAs that 
reflect/represent the pathological changes observed in Type 2 diabetes, namely 
hyperinsulinemia, impairment of GSIS, and development of insulin resistance (Y. 
Lee et al., 1994). ZDF pre-diabetic rats exhibited higher plasma FFA, triglyceride 
content, and basal insulin prior to onset of hyperglycemia due to loss of GSIS 
and GLUT2, an effect that was reversed by pair feeding with lean littermates (Y. 
Lee et al., 1994). The increase in basal and reduction in GSIS are similar to 
those observed by in vitro incubation of islets with long chain fatty acids (Y. P. 
Zhou & Grill, 1994). The impairment of GSIS upon long-term exposure of 
pancreatic islets to palmitate was shown to result from a decrease in PDH activity 
and an increase in PDH Kinase, which inactivates PDH by phosphorylating it (Y. 
P. Zhou & Grill, 1995).Influence of fatty acids on insulin secretion is time-
dependent; fatty acids are stimulatory upon short-term exposure in a manner that 
is dependent upon glucose concentration, but inhibitory to GSIS upon chronic 
intralipid infusion (Paolisso, Gambardella, et al., 1995a; Sako & Grill, 1990). In 
vitro findings are analogous, whereby acute treatment of beta cells with fatty 
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acids is stimulatory whereas chronic treatment is inhibitory for GSIS (Bollheimer, 
Skelly, Chester, McGarry, & Rhodes, 1998; Elks, 1993; Gravena, Mathias, & 
Ashcroft, 2002). The chain length and degree of unsaturation of fatty acids also 
have important properties since long chain and saturated fatty acids are more 
potent for GSIS (Stein et al., 1997). Fatty acids are thought to amplify insulin 
secretion acutely via fatty acid receptors such as GPR40 which may serve to 
increase fatty acid cycling (Itoh et al., 2003). Knockout of GPR40 has shown 
mixed results however, and its role remains controversial since some studies 
show a protective role, while others indicate no protection from high fat diet 
(HFD) (Poitout et al., 2010). Chronically, fatty acids are detrimental to GSIS via 
build up of toxic lipid metabolites, ceramides, and DAG (Kelpe et al., 2003), in 
addition to reduced insulin gene transcription (Ritz-Laser et al., 1999) and 
sustained oxidative stress (Hauck & Bernlohr, 2016; Ly et al., 2017). 
 
Saturated vs. Unsaturated Fatty Acids 
 
Palmitate lipotoxicity results from the beta cells’ inability to shuttle it into 
triglycerides for storage (Listenberger et al., 2003). Co-supplementation of 
unsaturated fatty acids, such as oleate, has been shown to rescue from the 
apoptotic effects of excess palmitate (Listenberger et al., 2003) (Maedler et al., 
2001). Moreover, palmitate elicits ER stress and results in striking morphological 
changes in ER, mitochondria, and Golgi (Karaskov et al., 2006) Desaturation in 
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beta cells is protective, as co-treatment with unsaturated fatty acids or 
overexpression of desaturases such as SCD1 ameliorates palmitate induced 
damage (Busch et al., 2005; Thörn, Hovsepyan, & Bergsten, 2010). From a 
physiological standpoint, it is more prudent therefore to utilize lipids that are 
physiologically more relevant either by supplementing beta cells with oleate, a 
lipid they are capable of handling, or of a combination of saturated and 
unsaturated fatty acids.  
 
Although unsaturated fatty acids such as oleate may be protective from 
inducing ER stress, they still play a role in contributing to beta cell dysfunction. 
Chronic infusion of oleate followed by application of hyperglycemic clamps 
results in impaired GSIS which is mediated by oxidative stress, an effect that is 
restored by treatment with antioxidants (Oprescu et al., 2007).   
 
Fatty acids amplify insulin secretion in the presence of glucose, while 
glucose excess is necessary for excess lipids to be toxic (Nolan, Madiraju, 
Delghingaro-Augusto, Peyot, & Prentki, 2006b) (Poitout et al., 2010) This 
suggests presence of coupling factors that mediate the effects of glucolipotoxic 
conditions (Prentki & Corkey, 1996).  
 
Increased tissue triglyceride content is correlated with the increased 
insulin resistance and hyperinsulinemia of obesity (Koyama, Chen, Lee, & Unger, 
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1997) Pre-diabetic islets display an increased lipogenic capacity which may 
constitute a compensatory response that exacerbates beta cell dysfunction (Y. 
Lee et al., 1997) 
 
Role of Mitochondria in Lipid-induced beta Cell Dysfunction  
 
Mitochondria are dynamic double membrane bound organelles that play 
central role in ATP production, and repeatedly undergo fission and fusion events 
allowing them to recover, share proteins and solutes, and increase their 
metabolic efficiency. Fusion triggers a fission event, producing two distinct 
daughter mitochondria, segregated by their difference in membrane potentials. 
One daughter mitochondrion is hyperpolarized and undergoes a subsequent 
fusion event, while the other daughter mitochondrion is depolarized and is 
targeted to undergo autophagy unless it recovers and repolarizes (Twig et al., 
2008). It is currently unknown mechanistically how this phenomenon occurs. 
Depolarized and fragmented mitochondria have been associated with a reduced 
respiratory capacity, increased oxidative damage and impaired insulin secretion, 
which is restored by shifting mitochondrial dynamics to a more fused state 
(Molina, Wikstrom, Stiles, Las, Mohamed, Elorza, Walzer, Twig, Katz, Corkey, & 
Shirihai, 2009a). As the primary fuel sensors in the cell an understanding of 
changes in mitochondrial bioenergetics function is crucial to understanding one 
aspect of the pathophysiology of diabetes.  
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Moreover, mitochondria play a particularly central role in the beta cell by 
integrating different types of fuels and producing metabolic signals that can be 
used to trigger secretion (Maechler & Wollheim, 2001). Beta cells devoid of 
mtDNA lose the ability to couple metabolism of nutrients to insulin secretion, 
highlighting a essential role for mitochondria in beta cells (Soejima et al., 1996) 
(Kennedy, Maechler, & Wollheim, 1998) (Tsuruzoe et al., 1998). Metabolites are 
broken down and electrons are stripped by the electron transport chain driving an 
increase in the mitochondrial membrane potential or proton motive force. The 
proton motive force is consumed either by the production of ATP (via increased 
energy demand) or is dissipated by proton leak. These cycles of exporting 
protons out via ETC activity and their re-entry via ATP synthase and/or leak 
determine mitochondrial oxygen consumption. The degree to which ATP 
production and oxygen consumption are coupled reflects bioenergetic efficiency. 
 
An intriguing and unique feature of beta cell mitochondria is their inherent 
bioenergetic inefficiency (Affourtit & Brand, 2009) (Wikstrom et al., 2012). This 
high inefficiency might serve beta cells to act as fuel sensors, and therefore 
metabolize and sense nutrients irrespective of their ATP demand.  
 
Characterization of T2D human islets display marked changes in 
mitochondrial features such as fragmented and hypertrophied morphology and a 
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reduction in membrane potential (Anello et al., 2005). In vitro studies of excess 
nutrient treatment of beta cells with lipotoxicity and glucolipotoxicity revealed that 
the increase in mitochondrial fragmentation results from a reduction in fusion. 
This fragmentation was primarily driven by the excess of non-physiological fatty 
acid concentration of palmitate (lipotoxicity) with a synergistic effect upon 
glucolipotoxicity (Molina, Wikstrom, Stiles, Las, Mohamed, Elorza, Walzer, Twig, 
Katz, Corkey, & Shirihai, 2009b). Long term exposure to excess palmitate has 
been associated with increased mitochondrial proton leak and excess ROS 
(Carlsson, Borg, & Welsh, 1999). This hinted at the possibility that identification 
of the source of leak may be a possible therapeutic target for diabetes. 
 
Mechansims for beta Cell Bioenergetic Inefficiency and its Relevance for T2D 
and beta Cell Dysfunction Induced by Lipids 
 
The mitochondrial proton motive force is primarily built to generate an 
energy potential driving the synthesis of ATP. Dissipation of the proton gradient 
via mechanisms that do not result in ATP production leads to mitochondrial 
uncoupling. Mitochondrial uncoupling may results from various changes in 
exchangers, ion channels etc. In brown adipose tissue, the main driver of 
leak/energy dissipation was discovered to be UCP1 (Nicholls & Locke, 1984). 
Researchers subsequently identified UCP homologs in other tissues. It was 
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strongly believed in the field that UCP2 is the main contributor of the leak in beta 
cells.  
 
The discovery of UCP2 by Fleury et al in 1997 generated a shift in the 
diabetes field, as it was proposed that UCP2, which shares 59% sequence 
homology with UCP1, is a ubiquitously expressed thermogenic protein. UCP2 
was determined to have a larger effect on mitochondrial membrane potential 
when expressed in yeast, while gene mapping in mouse and humans linked 
UCP2 to regions linked to hyperinsulinemia and obesity. UCP2 was hypothesized 
to play a role in obesity by regulation of body weight via its effect on energy 
expenditure. This prompted research towards characterization of this novel 
diabetes associated protein (Fleury et al., 1997).  
 
Overexpression Studies 
 
During that time, leptin was shown to induce UCP2 mRNA expression, 
increase enzymes involved in FA oxidation (CPT1 and ACO), while also 
decreasing intracellular lipid/triglyceride content (Y. T. Zhou et al., 1997). 
However, ZDF islets, which are insensitive to leptin, have reduced UCP2 
expression, increased TG content, and reduced GSIS. Introducing UCP2 to ZDF 
islets surprisingly rescued GSIS by promoting insulin gene expression, while 
displaying increased glucose and fatty acid oxidation, reduced ATP content, and 
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increase in ATP:ADP ratio, with no change in TG content (M. Y. Wang et al., 
1999). 
 
A contradictory finding was observed however, when UCP2 
overexpression was performed in normal rat islets. In this study, an inhibitory 
effect on GSIS was observed upon overexpression of UCP2 without an effect on 
insulin content (Chan et al., 1999). A follow-up study by the same group found 
that overexpression of UCP2 in normal rat islets decreased ATP content by 50%. 
The same study showed that rats on 3 weeks HFD increased expression of 
UCP2 in islets and increased in vitro basal insulin secretion from isolated islets, 
although there was no difference in in vivo fasting insulin secretion (Chan et al., 
2001). 
 
The role of UCP2 in reduction of GSIS upon chronic (72h) beta-cell 
exposure to excess FA oleate was also investigated. It was found that long term 
FA treatment results in increased UCP2 gene expression with concomitant 
reduction in cytosolic ATP/ADP ratio and plasma and mitochondria membrane 
potentials in response to glucose(Lameloise, Muzzin, Prentki, & Assimacopoulos-
Jeannet, 2001). 
 
However, beta cell specific overexpression of UCP2 in transgenic mice 
and INS-1 cells, did not reveal any changes in plasma glucose or insulin, GSIS, 
		 21 
mitochondrial membrane potential, oxygen consumption, or ATP/ADP ratio. The 
authors conclude that evidence suggests that UCP2 does not have a role in 
proton leak and that perhaps it has a protective role from the observation that 
cytokine-induced ROS production is reduced (Produit-Zengaffinen et al., 2006). 
 
The role of UCP2 in antioxidant stress defense was also explored. This 
study found a transient time dependent increase in UCP2 mRNA expression 
upon acute H2O2 induced oxidative stress, while the contrary was observed upon 
treatment with antioxidants (Vit E and selenite)	 (Li, Skorpen, Egeberg, 
Jørgensen, & Grill, 2001).  It was subsequently shown that transient 
overexpression of UCP2 plays a protective role albeit modest from H2O2 induced 
oxidative stress (Li et al., 2001). It is noteworthy to mention that INS1 cells 
detected higher UCP2 expression than pancreatic islets (Li et al., 2001). 
 
Knockout Studies 
 
Generation of a UCP2 knockout mouse model confirmed UCP2 is a 
negative regulator of insulin secretion. Ob/ob mice which exhibit increased UCP2 
mRNA and protein, were rescued by UCP2 KO displaying increased insulin 
secretion and improved glucose tolerance (C.-Y. Zhang et al., 2001). 
Subsequently, UCP2 KO mice under HFD were shown to promote better glucose 
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tolerance, attributed to improved insulin secretory capacity due to an increase in 
pancreatic beta cell mass and increased insulin content (Joseph et al., 2002). 
 
Evidence Against UCP2 Leak Role 
 
In marked contrast to previous UCP KO studies, Pi and colleagues 
showed in 3 independent mouse strains that KO of UCP2 induces oxidative 
stress while drastically impairing beta cell function with a marked reduction in 
GSIS (Pi et al., 2009). These completely opposing findings were attributed to 
differences in genetic background, which results in a genetic bias between KO 
and WT littermates, highlighting the importance of maintaining a congenic strain 
to avoid misinterpretation of findings (Pi & Collins, 2010). 
 
A beta cell specific UCP2 KO suggested a role for UCP2 in regulation of 
intracellular ROS, while substantial evidence indicated against an uncoupling role 
for UCP2. This was achieved by showing that lack of UCP2 did not have an 
effect on islet ATP content, glucose stimulated respiration, or uncoupled 
respiration, even though they had a higher basal OCR. The animals were 
surprisingly glucose intolerant. This was attributed to an increased alpha cell 
mass, increased glucagon content, and increased glucose induced glucagon 
secretion which the authors speculate is a result of the increased islet ROS 
content (Robson-Doucette et al., 2011). 
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Permeability Transition Pore as a Physiological Leak Mechanism 
Identification/Characterization/Regulation 	
It has long been recognized that mitochondrial calcium accumulation 
induces an increase in mitochondrial volume, reflected by increased light 
scattering of isolated mitochondria(Crofts & Chappell, 1965) (Chappell & Crofts, 
1965). This observation of calcium induced permeability transition led 
researchers to dissect the mechanisms by which this phenomenon occurs. 
Haworth and Hunter first showed that permeability transition occurs via a non-
selective channel which allows solute flux of substrates up to 1.5kD (Haworth & 
Hunter, 1979), while Crompton revealed that the pore opening has a diameter of 
2.3nm (Crompton & Costi, 1990). Calcium and oxidative stress synergistically 
induce pore opening (Crompton, Costi, & Hayat, 1987). Regardless of the size of 
the pore and its activation, this event would decrease mitochondrial efficiency, 
since opening of the pore results in dissipation of the proton motive force that is 
uncoupled to ATP production. However, it might likely impair mitochondrial 
respiratory function if uncontrolled. Evidence indicated permeability transition can 
be controlled and reversible, meaning that it can be a mechanism for regulation 
of bioenergetics efficiency and mitochondrial function. Numerous physiological 
factors, in addition to ROS and calcium, have been subsequently shown to 
modulate the probability of pore opening. Mitochondrial calcium overload (Wong, 
Steenbergen, & Murphy, 2012) (Sloan et al., 2012), depolarization (Bernardi, 
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1992), uncoupling (Petronilli, Cola, Massari, Colonna, & Bernardi, 1993), fatty 
acids (palmitate) (Petronilli et al., 1993), inorganic phosphate (Halestrap, 2009), 
ROS (Halestrap, Woodfield, & Connern, 1997; McStay, Clarke, & Halestrap, 
2002), potentiate mPTP opening, while adenine nucleotides (ADP and ATP), 
bongkrekic acid (ANT inhibitor) (Peng, Straub, Kane, Murphy, & Wadkins, 1977), 
BSA (via FA sequestration), NADH (Hunter & Haworth, 1979) Mg2+, CsA (Wong 
et al., 2012) and acidic pH (Halestrap, 1991) (Bernardi et al., 1992) prevent 
calcium induced permeability transition.  
 
Importantly, sustained opening of the permeability transition pore (PTP) 
depolarizes mitochondria, since proton leak dissipates the proton motive force. 
Bioenergetic failure ultimately ensues as the combination of uncoupled 
respiration and reversal of complex V (ATP synthase) will result in ATP depletion 
(Bernardi, 1999) (Halestrap, Clarke, & Javadov, 2004). Unfolding of 
mitochondrial cristae, and eventually membrane rupture leads to release of 
cytochrome c and other apoptotic stimuli (Halestrap, 2009) (Doran & Halestrap, 
2000) (Martinou & Green, 2001). However, this is not the only mechanism for 
cytochrome c release as evidence suggests this may occur via pore dependent 
and independent mechanisms(Alcalá, Klee, Fernández, Fleischer, & Pimentel-
Muiños, 2008; Doran & Halestrap, 2000) 
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Structure of the Permeability Transition Pore 
While characterization of factors that regulate the pore has been 
established, deciphering how the structural components of the PTP are 
interconnected has been challenging and remains an open question (Giorgio, 
Guo, Bassot, Petronilli, & Bernardi, 2017). Evidence for an inner mitochondrial 
membrane ion channel was achieved in 1987 by Sorgato et al, in which patch-
clamping of mitoplasts suggested this could be an inherent uncoupling protein 
(Sorgato, Keller, & Stühmer, 1987). It was subsequently proposed that the 
Mitochondrial Mega Channel (MMC) was in fact the mitochondrial permeability 
transition pore (mPTP), since it displayed similar response to elements that are 
known influence mPTP activity such as pH, Ca2+, and cyclosporine A (CsA) 
(Szabó & Zoratti, 1992) (Bernardi et al., 1992). Initially, the prevalent hypothesis 
in the field postulated that the pore consisted of multiple proteins including the 
voltage dependent anion channel (VDAC) in the outer membrane, adenine 
nucleotide translocator (ANT) and the mitochondrial phosphate carrier in the 
inner membrane, hexokinase (linked to VDAC in the cytosol), Cyclophilin D 
(CypD) in the matrix, and creatine kinase in the inner membrane space, among 
other associated regulatory proteins (Zamzami & Kroemer, 2001) (Giorgio et al., 
2017). However, genetic ablation of VDAC (Baines, Kaiser, Sheiko, Craigen, & 
Molkentin, 2007), ANT {Kokoszka:tk}, mitochondrial phosphate carrier (Gutiérrez-
Aguilar et al., 2014), benzodiazepine receptor (Šileikytė et al., 2014), still results 
in permeability transition, indicating these are dispensable. 
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Although it was known that CsA prevents permeability transition, 
Bernardi’s group was the first to show that this was via interaction with CypD 
(Nicolli, Basso, Petronilli, Wenger, & Bernardi, 1996). They subsequently 
provided the first evidence that CypD associates with the lateral stalk of the ATP 
Synthase, in which Pi enhanced, while CsA prevents, binding in a calcineurin 
independent manner (Giorgio et al., 2009). However, CypD was identified as only 
a regulator of PTP, since ablation of CypD necessitates a higher calcium 
threshold to activate permeability transitions (Basso et al., 2005). Furthermore, 
isolated mitochondria from mouse KO of CypD do not undergo permeability 
transition or swelling (Baines et al., 2005). In vivo, these mice are protected from 
ischemia reperfusion injury which is characterized by mitochondrial Ca2+ 
overload and oxidative stress (Baines et al., 2005). It is important to emphasize 
however, that although permeability transition requires a two-fold increase of 
Ca2+ in PPIF-/- mitochondria, CypD is not involved in other factors that sensitize 
PTP opening such as membrane potential, oxidative stress, and adenine 
nucleotides. 
 
Cyclophilin D is a peptidyl prolyl cis-trans trans-isomerase that possesses 
chaperone properties and is involved in protein folding (Elrod & Molkentin, 2013). 
The full length protein, including the mitochondrial targeting sequence is 22kDa, 
while the matrix targeted, cleaved isoform is 18kDa (N. Johnson, Khan, Virji, 
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Ward, & Crompton, 1999) The crystal structure has revealed that cyclophilin D 
contains eight β-strands, two α-helices, and one 310-helix (Kajitani et al., 2008). 
While not much is known in terms of transcriptional regulation of CypD(Elrod & 
Molkentin, 2013), several modes of posttranslational modifications have been 
identified. Cyclophilin D has been suggested to be regulated by phosphorylation 
via glycogen synthase kinase 3β (GSK3β) (Xi, Wang, Mueller, Norfleet, & Xu, 
2009), although this is disputed since it remains incompletely understood how 
kinases and phosphatases are regulated in the mitochondrial matrix(Elrod & 
Molkentin, 2013). It has also been proposed that Sirt3 may inhibit PTP via 
deacetylation of CypD at lysine 166(Hafner et al., 2010). Furthermore, S-
nitrosylation of Cysteine 203 displays a protective effect by making cells immune 
to ROS-induced death and mitochondrial swelling. It is thought that this occurs 
from prevention of cysteine oxidation(T. T. Nguyen et al., 2011b). 
 
Bernardi and colleagues introduced a revised model of the PTP in which 
components have been simplified down to dimers of the ATP synthase and 
cyclophilin D. The ATP synthase assembles into zipper-like dimers, where CypD 
associates with the lateral stalk of the ATP synthase pore(Giorgio et al., 2009). 
Interaction was shown to be regulated by CsA, as it dissociates CypD and 
increases catalytic activity of the ATP synthase(Giorgio et al., 2009). Subsequent 
work via immunoprecipitation of individual b, c and OSCP subunits of the 
peripheral stalk revealed the OSCP subunit as the binding partner of 
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CypD(Giorgio et al., 2013). Reconstitution of dimers into lipid bilayers showed 
that ATP synthase can form a conductance channel that is sensitive to 
benzodiazepine 423 (Bz-423) which sensitizes the pore to Ca2+ (Giorgio et al., 
2013). Silencing OSCP was found to increase PTP sensitivity Ca2+ to as well 
(Giorgio et al., 2013). While the simplified model of the ATP synthase dimers and 
CypD is fairly accepted, it remains to be determined by what mechanism the 
dimers form and how PTP opening occurs. Permeability transition was proposed 
to occur via the c-ring (Bonora et al., 2013) (Alavian et al., 2014). However, the 
Walker lab demonstrated that deletion of the c-ring still allowed calcium induced 
permeability transition (He et al., 2017b). Simulation models also dismiss this 
theory, since simulations indicate that the c-ring cannot be in a hydrated state, 
eliminating the possibility of ion conductance (W. Zhou, Marinelli, Nief, & Faraldo-
Gómez, 2017). The Bernardi lab has suggested a plausible mechanism. They 
have hypothesized that calcium binding in the F1 β-subunit induces a 
conformational change in the OSCP subunit, thereby mechanically inducing PTP 
opening as the lateral stalk is thought to be a hinge, whereby regulation occurs at 
a 100 Angstrom distance (Giorgio et al., 2017). This remains controversial, 
however, since two recent papers show contradictory findings regarding the roles 
of the OSCP and peripheral stalk in permeability transition (Antoniel et al., 2018) 
(He, Carroll, Ding, Fearnley, & Walker, 2017a). 
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Pathophysiological Roles of PTP 
 
Sustained PTP opening results in a collapse of the mitochondrial 
membrane potential, loss of ATP production, equilibration of solutes, 
mitochondrial swelling and apoptotic release of cytochrome c (Bernardi, Rasola, 
Forte, & Lippe, 2015; Petronilli, Nicolli, Costantini, Colonna, & Bernardi, 1994). 
Considerable research has implicated dysfunctional PTP regulation in various 
diseases. PTP opening has been linked mechanistically to the damaging effects 
observed in ischemia-reperfusion injury of the heart (Baines et al., 2005; Griffiths 
& Halestrap, 1993; Piot et al., 2008; Sloan et al., 2012), muscle fiber loss in 
Ullrich congenital muscular dystrophy(Irwin et al., 2003; Sorato et al., 2014), as 
well as Duchenne muscular dystrophy(Reutenauer, Dorchies, Patthey-Vuadens, 
Vuagniaux, & Ruegg, 2008). Neurological diseases, such as Alzheimer’s, in 
which beta amyloids augment PTP induction (Du et al., 2008), and multiple 
sclerosis (Forte et al., 2007) also implicate PTP opening induced damage. 
Excessive PTP opening also drives diet-induced insulin resistance in mice 
(Taddeo et al., 2014). Knockout of CypD or use of PTP inhibitors is profoundly 
protective in all of these pathologies, exposing the PTP as an important 
therapeutic target.  
 
In contrast, some cancer cells evade cell death by a reduction of pore 
opening resulting from desensitization (Bernardi et al., 2015). Hexokinase II 
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promotes survival of these cells, not only through its antioxidant function (Pantic 
et al., 2013), but also via its interaction with the OMM (Engelman, 2009), which 
maintains the PTP in a closed conformation (Chiara et al., 2008). 
Physiological Role of PTP 
 
While the PTP has been well characterized in terms of its damaging 
effects in diseased states and induction of cell death, its normal physiological role 
has not been extensively characterized and remains an open question. Evidence 
indicates that the PTP may undergo flickering, a low-conductance state of 
opening, which enables transmission of small ions such as H+, K+, and Ca2+, but 
not larger solutes such as sucrose (Ichas, Jouaville, & Mazat, 1997). Flickering 
allows the propagation of Ca2+ waves, much like action potentials in excitable 
cells. The rapid transients are reflected by rapid changes in membrane potential, 
where depolarization is associated with increases in matrix calcein, an indication 
of PTP opening (Hüser, Rechenmacher, & Blatter, 1998). This phenomenon of 
calcium induced calcium release, is observed in isolated mitochondria as well as 
intact cells. Cyclosporin A prevents Ca2+ efflux in cardiomyocytes (Altschuld et 
al., 1992), indicating that the low conductance state of the PTP must have a 
physiological role (Ichas & Mazat, 1998). Ablation of CypD in the heart 
exacerbated pressure-overload-induced cardiac dysfunction and hypertrophy by 
increasing matrix calcium, cardiac dehydrogenase activity and the ratio of 
glucose to fatty acid oxidation (Elrod et al., 2010). 
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Figure 1.1. Conventional Model for Progression of T2D.  
In	 the	 progression	 of	 T2D	 it	 is	 generally	 believed	 that	 insulin	 resistance	 of	 the	peripheral	 tissues	 such	 as	 fat,	 liver,	 and	 muscle	 leads	 to	 compensatory	 basal	hypersecretion	of	insulin.	Insulin	resistance	alone	does	not	cause	diabetes.	It	is	only	when	the	compensatory	increased	beta	cell	workload	ultimately	results	in	beta	cell	failure	that	hyperglycemia	ensues	and	diabetes	occurs.	
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Figure 1.2. Alternative Model for T2D Progression: Basal Hyperinsulinemia 
Leads to T2D.  
Excess	nutrients	result	 in	basal	hypersecretion	of	 insulin	in	the	obese.	We	propose	an	alternate	model	of	diabetes	progression,	in	which	basal	hyperinsulinemia	may	be	a	primary	defect	driving	peripheral	tissue	insulin	resistance,	ultimately	resulting	in	beta	 cell	 failure	 and	hyperglycemia.	 It	 is	unknown	what	mechanisms	govern	basal	hypersecretion	of	insulin.		
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CHAPTER TWO: Methods 
 
Cell Culture and Reagents 
 
INS 832/13 cells were cultured in RPMI 1640 supplemented with 
10%FBS, 10mM Hepes, 1mM Pyruvate, 50U/mL penicillin, 50g/mL streptomycin 
and 50uM 2-b-mercaptoethanol. Cells were cultured in either 11mM glucose or in 
4mM glucose. A minimum period of 2 weeks in 4mM glucose was required for 
experiments of the 4mM glucose cells.  
 
Animals 
 
Islets were isolated from 12-14week old C57BL/J mice ordered from Jax 
labs. Mice were housed at University of California Los Angeles Animal 
Resources Facility. Animal care was in accordance with NIH guidelines and 
UCLA IACUC approval (UCLA protocol #16-018). Mice were housed in a 
12hr/12hr light dark cycle and maintained at 68-72F and provided with water and 
food ad libitum until day of isolation. A maximum of 5 mice were housed per 
cage. Cyclophilin D mice were purchased from Jackson Laboratories 
(Stock 00907, B6;129-Ppiftm1Jmol/J, generated by Dr. Jeffrey Molkentin, PMID: 
15800627). WT and CypD KO littermate mice were produced from heterozygous 
breeding pairs, deriving from a male KO mouse and a female WT control 
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(Jackson Laboratories, Stock 101045, B6129SF2/J). Animals were sacrificed by 
isofluorane (UCLA) followed by cervical dislocation.  
 
Genotyping 
 
Mouse genotyping was outsourced to Transnetix. PCR of tail clips was 
performed by the protocol from Jax labs. The excised bands were 600bp for the 
mutant, and 850bp for WT. The following primers were used CTC TTC TGG 
GCA AGA ATT GC for (WT #8584), ATT GTG GTT GGT GAA GTC GCC 
(common #8585), GGC TGC TAA AGC GCA TGC TCC (mutant forward #8586) 
 
Islet Isolation 
 
Pancreatic islet isolations were performed as previously described 
(Wikstrom et al., 2013). After sacrificing the animals, an incision was made to 
expose the body cavity. The fat pads and viscera are gently moved down and 
towards the right, to expose the bile duct. Clamping the juncture of the bile duct 
and intestines is necessary to secure inflation of the pancreas. Islets of 
Langerhans were isolated by collagenase perfusion via the bile duct with RPMI 
media containing collagenase at a concentration of 1mg/mL. Perfusion via 
anatomical structures allows for better inflation of the pancreas and results in a 
higher islet yield. Pancreata were collected and left on ice for a maximum of one 
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hour. Islets were digested in 37°C water bath for 10min, after which they were 
washed 3x with RPMI media containing FA-free BSA at a concentration of 
1g/100mL to stop digestion. Histopaque 1077 gradient centrifugation was 
performed to separate islets. Islets were subsequently collected and washed 
twice with FA-free BSA RPMI solution, after which they were picked and cultured 
overnight in beta cell media consisting of RPMI, 10%FBS, 50U/mL penicillin, and 
50g/mL streptomycin. An average yield of 100 islets was obtained per mouse. 
 
Insulin Secretion Assay- INS1  
 
INS1 insulin secretion assays were performed in a static incubation on 
cells that have reached 70-80% confluence in 96-well black-sided clear bottom 
plates. Cells were pre-incubated in 2mM glucose RPMI containing 10%FBS, 
10mM Hepes, 1mM Pyruvate, 50U/mL penicillin, and 50g/mL streptomycin. This 
was followed by a 30 minute pre-incubation in 2mM glucose Krebs at 37°C. 
Insulin secretion samples were collected after a subsequent 1 hour incubation at 
37°C in either 2mM glucose Krebs or 12mM glucose Krebs for basal or glucose 
stimulated insulin secretion, respectively. Krebs solution consisted of 119mM 
NaCl, 20mM Hepes, 4.6mM KCl, 1mM MgSO4, 0.15mM Na2HPO4, 0.4mM 
KH2PO4, 5mM NAHCO3, 2mM CaCl2, 0.5%BSA, pH 7.4. 
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Insulin Secretion Assay-Islets 
 
Intact islets (6 islets/well) were pre-incubated in 3mM glucose Krebs 
solution for 30min in a 37°C H2O bath. This was followed by a 45 minute 
incubation in either 3mM or 16.7mM glucose Krebs solutions for basal or glucose 
stimulated insulin secretion, respectively. Leucine/Glutamine, Oleate/Palmitate, 
MnTBAP, and Nim811 were added during these incubations at the 
concentrations indicated.  
 
Insulin Measurements 
 
An HTRF insulin assay kit was used to measure insulin secretion (CisBio, 
Bedford, MA). The assay consists of a FRET-based sandwich immunoassay with 
Europium Cryptate (Eu-K) and allophycocyanin (XL665) antibodies. Secretion 
samples were appropriately diluted in a 96-well plate after which 10μL of sample 
and 10μL of the antibody mix were dispensed into white 384-well plates (Greiner 
catalog # 784076) and incubated overnight at room temperature. A Tecan Infinite 
M1000 or Spark 10M plate reader was used to measure time-resolved 
fluorescence at emission wavelengths of 665nm (XL665) and 620nm (Eu-K). 
Insulin concentration of the samples was calculated from an insulin standard 
curve. Values that did not fall within the standard curve were excluded or 
rediluted and reassayed. 
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Western Blotting 
 
Protein isolation was performed by washing islets with PBS on ice 
followed by addition of RIPA lysis buffer (Santa Cruz Biotechnology) with addition 
of 2% Triton-X-100 and protease inhibitors (Santa Cruz Biotechnology) for 5 
minutes. Islet lysates were collected and continued to sit on ice for 30min. 
Lysates were then centrifuged at 12,000 rpm for 10min at 4C after which the 
supernatant was collected. A BCA assay (Thermo Fisher Scientific) was used to 
determine protein concentration. Samples were reduced and denatured by 
addition of β-mercaptoethanol and 4x NuPAGE LDS sample buffer (Invitrogen) 
followed by boiling at 95C for 10min. Samples were loaded on a 4-12% 
polyacrylamide gradient gel and a wet transfer to a PVDF membrane was 
performed overnight at 4C. The membrane was blocked with 5% BSA PBS 
solution containing 0.1% Tween-20 (PBST) for 1 hour after which it was 
incubated overnight at 4C in the primary antibodies indicated. For cyclophilin D 
the antibody used was mouse monoclonal cyclophilin F (Abcam, ab110324) at 
1:1000 dilution. The membranes were then washed three times in PBST for 5 
min and subsequently incubated in the appropriate anti-Rabbbit or anti-Mouse 
IgG secondary antibodies for 45min at room temperature. Membranes were 
again washed 3 times with PBST.  A chemiluminescent Supersignal West Femto-
Max Sensitivity Substrate (Cat. #34095 ThermoScientific) was used to detect 
protein signal. B-actin or GAPDH were used as loading controls to correct for 
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protein loading. Densitometry of changes in protein expression was performed in 
ImageJ software. 
 
Preparation of Fatty Acids 
Palmitate-BSA 
Palmitate was complexed to BSA at a ratio of 4:1. Palmitic acid (Sigma) 
was dissolved in DMSO to make a final concentration of 400mM. The Palmitate-
DMSO was then dissolved in a 6.7% fatty acid-free BSA RPMI 1640 no glucose 
solution at 45°C to produce a 10x stock of 4mM Palmitate(Las, Serada, 
Wikstrom, Twig, & Shirihai, 2011). Stocks were stored at -80°C. On the day of 
treatment, the solution was added to 1% FBS RPMI solution containing 50U/mL 
penicillin, 50g/mL streptomycin and 11mM glucose or as indicated. Solutions 
were then adjusted to pH 7.4, filtered and cells treated for indicated time periods. 
 
BSA Control 
For the BSA control, a 6.7% FA-free BSA RPMI solution containing 1% 
DMSO was made to prepare a 10x stock solution(Las et al., 2011).. Stocks were 
stored at -80°C. On the day of treatment, the solution was added to 1% FBS 
RPMI solution containing 50U/mL penicillin, 50g/mL streptomycin and 11mM 
glucose or as indicated. Solutions were then adjusted to pH 7.4, filtered and cells 
treated for indicated time periods. 
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Oleate-Palmitate BSA 
Sodium palmitate (Sigma, cat. # P9767) and sodium oleate (Sigma, cat. # 
O3880) were complexed to Ultra FA-free BSA (Roche Applied Science, cat. # 
03117405001) in a 150mM NaCl solution at 37°C at a FA:BSA ratio of 2:1 (1:1 
ratio of oleate:palmitate) to produce a 10mM OP stock solution(Trudeau et al., 
2016). The pH of the solutions was then adjusted to 7.4 using NaOH, filtered and 
stored at -20°C. The solutions were diluted in 1% FBS RPMI solution containing 
50U/mL penicillin, 50g/mL streptomycin and 11mM glucose before treating INS1 
cells or mouse islets for time indicated. 
 
Oleate-FBS  
Oleate 3.15 mol/L (Sigma O1008-5g) was dissolved in DMSO to a final 
concentration of 100mM or 200mM oleate-DMSO. The oleate-DMSO solution 
was then complexed to FBS serum at 57°C while vortexing to produce a 10x 
stock(Erion et al., 2015). 10x stock solutions of 1mM and 2mM oleate were 
stored at -80°C. For the control, FBS containing 1% DMSO was stored at -80°C 
as a 10x stock. Stock solutions were diluted in 0% FBS RPMI media containing 
either 4mM or 11mM glucose at the indicated concentrations.  
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Respirometry/O2 Consumption 
A seahorse extracellular flux analyzer XF96 (Seahorse Bioscience, 
Billerica, MA) was used to assess changes in oxygen consumption in INS-1 cells 
and intact islets as previously described (Wikstrom et al., 2012). For single islets 
respirometry, islets were transferred to 3mM glucose (basal) Seahorse media. 
Single islet respirometry was performed in PDL-coated 96-well XF plates. To 
maintain accurate OCR measurements, wells were plated with 1.5uL matrigel, to 
which islets were hand picked and carefully placed in center of the well. 6-8 wells 
of islets were seeded at a time. Matrigel was allowed to solidify for 2-3min, before 
addition of 150uL Basal SH media. Basal SH media was defined as 2.8mM 
glucose Seahorse XF Base Medium (Catalog # 102353-100) in 0.1%FBS. For 
port injections, various nutrients indicated were injected in port A, followed by 
final concentrations of 4.5 μM Oligomycin in port B, 1 μM FCCP in port C, and 
2.5 μM Antimycin A in port D. All compounds were calculated such that final 
concentrations in well reflect total volume of well upon injection. Start volume 
was 150uL, and all injections were 25uL for a final volume of 250uL upon 
completion of the assay. 
 
Quantification of Lipid Content 
Changes in intracellular lipid content were determined by fixing cells with 
4% paraformaldehyde (PFA) for 15 minutes, washing twice with PBS and 
staining with Bodipy (493/503) and Hoechst (to identify nuclei) for 15 minutes. An 
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Operetta high throughout imaging system was used to image 96-well black sided, 
clear bottom plates with preset filters for green and blue excitation. Prior to 
imaging every experiment, testing of optimal z-plane and exposure was 
determined to gain best focus and signal/noise ratio. Operetta STAR analysis 
software was used to determine nuclei to identify cell numbers, while Bodipy493 
(green) signal/channel was used to determine cell area, lipid droplets intensity, 
number and area.  Quantification of lipid droplet number per cell number was 
deemed to be the parameter most reflective of changes in lipid content. 
 
Reactive Oxygen Species Measurements 
	CM-H2DCFDA	(Invitrogen,	5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein	diacetate,	acetyl	ester),	a	molecular	probe	for	hydrogen	peroxide	was	used	to	detect	changes	 in	 reactive	 oxygen	 species.	 Islets	 were	 dispersed	 and	 seeded	 in	matrigel	(BD	 Matrigel™	 Basement	 Membrane	 Matrix)	 in	 96-well	 cell	 culture	 plates.	Dispersed	islet	cells	were	kept	overnight	 in	β-cell	medium.	The	following	day	cells	were	 loaded	with	10	µM	CM-H2DCFDA	 (Invitrogen)	 for	one	hour	at	3mM	glucose.	Cells	were	washed	twice	with	Krebs	buffer	solution	followed	by	15min	incubation.	A	Tecan	 Infinite	 M1000	 plate	 reader	 was	 used	 to	 measure	 fluorescence	 emission	detected	 at	 520	 nm	 at	 37°C.	 Unstained	wells	were	 used	 as	 negative	 controls	 and	positive	controls	were	performed	with	tert-butyl	hydrogen	peroxide	(Sigma).	
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Introduction 
 
Diabetes and obesity are associated with increased levels of free fatty 
acids in the circulation (Y. Lee et al., 1994). This suggests the hypothesis that 
overconsumption of nutrients leads to beta cell dysfunction. A hallmark of T2D is 
an impaired capacity of pancreatic beta cells to secrete insulin in response to 
nutrients. Different labs have employed similar but unique models of excess 
nutrients to investigate this hypothesis such as lipotoxicity (excess lipids), 
glucotoxicity (excess glucose), and glucolipotoxicity. The objective herein is to 
optimize an in vitro system of glucolipotoxicity mimicking the pathophysiological 
changes to beta cell function in vivo during diabetes progression. That is, excess 
fatty acid treatments that result in a reduction of glucose stimulated insulin 
secretion, while increasing basal insulin secretion (Sako & Grill, 1990; Y. P. Zhou 
& Grill, 1994). This would provide a system whereby the mechanisms resulting in 
beta cell dysfunction could be further dissected and characterized. 
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Results 
Optimization of Palmitate Lipotoxicity Model 
 
Free fatty acids are insoluble in aqueous solutions and therefore are 
complexed to BSA to increase solubility. This mimics the process by which fatty 
acids are normally transported through the circulatory system on albumin. Our 
lab has previously established a protocol in which palmitate is complexed to BSA 
at a FA:BSA ratio of 4:1 to make a 10x stock solution.(Las et al., 2011). This 
protocol is technically challenging and has proved difficult to reproduce, since it 
has not been optimized and there is variability in batch-to-batch preparations. 
The concentration of 0.4mM palmitate at a 4:1 ratio of FA:BSA is expected to 
reduce glucose stimulated insulin secretion (GSIS) as previously reported (Las et 
al., 2011; Trudeau et al., 2016). In Figure 3.1A the clonal rat beta cell line INS1 
was cultured in 11mM glucose and concomitantly treated with the respective 
concentrations of palmitate indicated for 16-24 hours, after which an insulin 
secretion assay was performed. However, as can be seen in Figure 3.1A, the 
expected reduction in GSIS is not observed. We reasoned that this might be due 
to oxidation of the palmitate stock. To test this, the same BSA:palmitate 
conjugation protocol was executed with fresh palmitate stocks from various 
vendors (Figure 3.1B,C,D). INS1 cells cultured in 11mM glucose were similarly 
treated with palmitate from several sources at the designated respective 
concentrations in Figure 3.1B,C,D. These data do not show a significant 
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inhibition of GSIS at any of the concentrations used. There was a trend, albeit 
insignificant, in the BSA control, to reduce GSIS as compared to the INS1 
control. A titration of palmitate was performed to show that a low dose of 
palmitate may be necessary to overcome the effect of FA-free BSA control on 
insulin secretion, since the controls are reduced to 1%FBS with addition of 
100uM FA-free BSA. This could be due to the fact that BSA acts as a sink for 
lipid, since free fatty acids undergoing diffusion through the plasma membrane 
will be trapped outside the cell upon interacting with BSA (Hamilton, 1999).  
 
We next sought to determine the relative contributions of palmitate and 
glucose to impairment of insulin secretion. INS1 cells cultured in 11mM glucose 
were treated either with 20mM glucose (GT), 0.4mM palmitate in 11mM glucose 
(LT) or a combination of 20mM glucose + 0.4mM palmitate (GLT). As can be 
seen in Figure 3.2A, the addition of palmitate (LT) increases basal insulin 
secretion, while addition of glucose (GLT) caused a further increase. However, 
the data indicate that the primary insult on GSIS is glucotoxicity. These 
experiments were performed in 1%FBS. Since INS1 cells are routinely cultured in 
10% FBS, we hypothesized that serum reduction would sensitize beta cells to 
glucotoxic conditions. Hence, a dose response of various glucose concentrations 
was carried out with various serum concentrations (10% or 1%FBS). INS1 cells 
were co-cultured in the respective glucose concentrations indicated in Figure 
3.2B,C at either 10% or 1%FBS. The results of these insulin secretion assays 
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indicated an increased sensitivity to the glucotoxic insult at lower serum 
concentrations. Moreover, glucotoxicity reduces GSIS in a dose-dependent 
manner. 
 
Since fatty acids are typically complexed to BSA, this necessitates that the 
respective controls be treated with similar concentrations of FA-free BSA. 
Interestingly, we have found that overnight culture of INS1 cells in FA-free BSA 
results in a reduction of beta cell capacity to secrete insulin upon glucose 
stimulation in a dose dependent manner. Figure 3.3A,B demonstrate a reduction 
of GSIS in INS1 cells upon overnight exposure to the designated concentrations 
of BSA. 
 
BSA has been shown to stimulate insulin secretion in acute conditions 
(Haber et al., 2003). In contrast, our data revealed a reduction of insulin secretion 
upon treatment with BSA in a dose dependent manner. These findings prompted 
us to examine the changes in intracellular lipid with various models of lipotoxicity. 
Erion et al recently demonstrated a left shifted response, or increased sensitivity 
of beta cells when cultured at high glucose concentrations or in excess lipid. 
These findings correlated with intracellular lipid content(Erion et al., 2015). To 
determine if changes in intracellular lipid could confound our results, we 
performed a comparison of our lipotoxicity protocol with that of Erion et al. INS1 
cells grown in 11mM glucose were treated in either 10%FBS (normal culture 
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conditions), 50µM BSA 1%FBS, 100µM BSA 1% FBS, 100µM Oleate 10%FBS, 
or 400µM Palmitate 1%FBS. After 16h treatment with the respective nutrients, 
cells were fixed and stained with Bodipy493 and Hoescht to quantify lipid 
droplets and cell nuclei respectively. A high throughput imager (Operetta), with 
fixed filter sets, Bodipy493 Ex/Em 460-490, 500-550 and Hoescht Ex/Em 360-
400, 410-480 was used to acquire images and quantify lipid droplets. We 
observed striking differences in lipid content among these conditions (Fig 3.4). 
The highest intracellular lipid content was observed with 100µM oleate in 10% 
FBS, while 100µM BSA in 1%FBS showed a drastic reduction in lipid content and 
number of lipid droplets per cell. Our presumed lipotoxic condition of 0.4mM 
palmitate in 1% FBS displayed a lower lipid content relative to normal 10% FBS 
culturing conditions. These data indicated that reduction of FBS to 1%, while 
warranted to increase BSA bound lipid of interest delivery to the cell, reveal a 
stark contrast to normal culture conditions, which may lead to misinterpretation of 
findings. It is important to emphasize that when a comparison to normal 10%FBS 
conditions is made, the reduction in insulin secretion is not significant, while the 
effect on intracellular lipid is substantial. 
 
Having exposed intracellular lipid content as an important parameter 
influencing beta cell function, we resolved to develop a more suitable 
pathophysiological excess nutrient environment under which beta cell 
dysfunction may be probed. Beta cells have been shown previously to undergo 
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ER stress crystallization, since they are less equipped to handle saturated fatty 
acids due to lack of desaturase expression (Busch et al., 2005; Karaskov et al., 
2006; Thörn et al., 2010). As such, it is more reasonable to utilize oleate, a lipid 
moiety the beta cell is equipped to handle. In vivo saturated fatty acids are never 
the sole fatty acid available to a cell. Given that beta cells are physiologically 
exposed to lower glucose concentrations than the normally accepted in vitro 
culturing conditions of 11mM glucose, we chronically cultured beta cells at 4mM 
glucose. INS1 cells were then treated at either 100µM or 150µM oleate at 4mM 
glucose for lipotoxicity or at similar concentrations of oleate while increasing 
glucose to 11mM as a glucotoxicity model. These studies revealed that 150uM 
oleate at 4mM glucose almost doubled basal insulin secretion while reducing 
GSIS (Fig.3.5A, B). Additionally, these data do not display a difference in insulin 
content as compared to the controls. Utilization of oleate directly complexed to 
BSA present in FBS as a lipotoxicity model may serve as a suitable model for the 
early changes in beta cell dysfunction during diabetes development, in which 
insulin is hyper-secreted at fasting/basal glucose levels, prior to manifestation of 
other long-term impairments. 
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Discussion 
 
In vitro models of excess nutrients are valuable tools to investigate 
pathophysiological effects on cellular function. There is no clear consensus in the 
literature or guidelines for what an appropriate lipotoxicity model is. Additionally, 
the protocols employed to deliver fatty acids to cells are variable. Given that our 
palmitate model of lipotoxicity was challenging to reproduce, we attempted to 
understand the difficulties encountered. A key limitation of our system is the 
singular utilization of palmitate devoid of an unsaturated fatty acid in combination. 
We sought modifications that are experimentally reproducible and physiologically 
sound. 
 
Technical Considerations 
 
Developing an in vitro model of lipotoxicity is technically challenging due to 
the various elements involved. Batch to batch variability in fatty acids 
preparations affects reproducibility of data. We have determined that the source 
of palmitate may interfere with results, for reasons such as purity or oxidation of 
the samples. Since free fatty acids must be complexed to BSA to increase 
solubility and delivery to the cell, care must also be taken as to the source of 
BSA used. It is imperative that FA-free BSA is used. Furthermore, the method of 
purification is also important to avoid other contaminants, which may elicit an 
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inflammatory response, and thereby mask the influence of fatty acids, while also 
confounding interpretation of results. The temperature at which fatty acids are 
complexed is yet another critical parameter, since certain above threshold high 
temperatures may lead to aggregation of fatty acids. In our experiments, palmitic 
acid was dissolved in DMSO. Hence, it’s also crucial to make certain that the 
palmitate is well dissolved in this organic solvent to ensure equimolar delivery of 
lipid to bind BSA during preparation of different lots. 
 
Glucotoxicity is a Prerequisite for Detrimental Effects of Excess Lipids 
 
Our findings indicate that 16h chronic incubation with glucose is the 
primary contributor to decreased beta cell function and reduction in GSIS in 
models of GLT. This is not a surprising result, since it has previously been 
shown(J. Fu et al., 2017) Glucose processing entails two energy-demanding 
processes. While metabolism of glucose is an overall energy generating process, 
ATP is required for the secretion of insulin. Importantly, ATP is required in the 
first committed step of glycolysis in which glucose phosphorylation is required to 
generate G-6-P. ATP is again required in the second committed step at PFK in 
conversion of fructose 6-phosphate to fructose 1,6-bisphosphate. Excess 
glucose demands ATP for glucose to be phosphorylated by hexokinase and PFK, 
therefore increasing energy demand. Cells chronically cultured in 11mM glucose 
vs. 4mM glucose have increased lipids. Glucose increases intracellular lipid by 
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providing a glycerol backbone for triglyceride synthesis. This in turn may result in 
futile TG/FFA cycling (Nolan, Madiraju, Delghingaro-Augusto, Peyot, & Prentki, 
2006b). 
Serum is Protective from Glucotoxicity  
 
My data show that culturing INS1 cells in reduced serum sensitizes them 
to glucotoxicity. This suggests the presence of protective lipid moieties or factors 
that are lost upon serum reduction. In the case of higher serum, more glucose 
may be shuttled away from mitochondrial oxidative metabolism towards lipid 
esterification and formation of TG, or diverted to glycerol release. A recent study 
has shown a linear relationship for glycerol release, and lipid synthesis (FFA 
release FFA content and TG content) with increasing concentrations of glucose 
as mechanisms for excess fuel detoxification in beta cells (Mugabo et al., 2017). 
Ex vivo treatment of beta cells with serum from calorie-restricted animals vs. ad 
libitum fed animals (which is arguably more physiological) protects beta cells 
from glucolipotoxicity, by maintaining mitochondrial fusion capacity and 
respiratory function thereby indicating that factors present in the serum 
independent of nutrients influence adaptive responses to nutrient insults 
(Cerqueira et al., 2016). Alternatively, a potential protective factor in serum is 
GLP-1. Beta cells have been shown to secrete GLP-1 which contributes to their 
basal activity (Masur, Tibaduiza, Chen, Ligon, & Beinborn, 2005). GLP-1 may be 
supported by factors in the serum, and displays anti-apoptotic effects and is 
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protective from glucotoxicity and lipotoxicity (Buteau et al., 2004) (Cornu & 
Thorens, 2009). Discerning the effects of FAs vs. other factors in the serum, 
however, would necessitate treatment with equimolar concentrations of FA 
perhaps via utilization of delipidated serum. 
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Figure 3.1.  Optimization of Palmitate Lipotoxicity Model. 
(A)	INS1	cells	cultured	in	11mM	glucose	media	were	treated	under 	concentrations	of	 palmitate	 indicated	 for	 16-20h,	 after	 which	 an	 insulin	 secretion	 assay	 was	performed.	n=3	*compared	to	BSA	2mM	glucose	p<0.0001	(B),	(C),	(D)	n=2.		 	
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Figure 3.2.  Comparison of Different Models of Excess Nutrients on beta 
cell Insulin Secretion. 
INS1	 cells	 cultured	 in	 11mM	glucose	media	were	 treated	under	 different	 nutrient	conditions	 for	 16-20h,	 after	which	 an	 insulin	 secretion	 assay	was	 performed.	 (A)	Glucotoxicity	 (GT)	 20mM	 glucose,	 Lipotoxicity	 (LT)	 0.4mM	 palmitate,	 11mM	glucose,	Glucolipotoxicity	 (GLT)	0.4mM	palmitate,	20mM	glucose,	n=3	*	 compared	to	BSA	12mM	glucose,	**compared	to	GLT	12mM	glucose,	#	compared	to	GT	12mM	glucose.	 Respective	 p	 values	 indicated	 above	 each	 condition.	 (B),(C).	 INS1	 cells	cultured	 in	11mM	glucose	were	 treated	under	glucose	concentrations	as	 indicated	in	either	1%	or	10%	FBS,	n=3	
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Figure 3.3.  Influence of Serum reduction or addition of FA-free BSA on 
insulin secretion 
(A)	INS1	cells	cultured	in	11mM	glucose	were	plated	in	96-well	plates	and	grown	to	70%	confluence.	Cells	were	 treated	with	either	10%FBS	RPMI1640	INS1	Media	or	1%FBS	 RPMI	 +	 100uM	 FA-free	 BSA	 for	 16-20h.	 n=3,	 *p<0.0001	 (B)	 INS1	 cells	cultured	 in	 11mM	 glucose.	 Titration	 of	 FA-free	 BSA	 performed	 at	 concentrations	indicated	 in	1%FBS	media	 for	16-20h.	n=2.	For	 insulin	 secretion	assay,	 cells	were	preincubated	 in	 2mM	RPMI	 for	 2h	 after	which	 secretion	 assay	was	 performed	 in	Krebs	as	described	in	methods.	
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Figure 3.4 Reduction of Serum Depletes Intracellular Lipid 
INS1	 cells	were	 grown	 to	70%	confluence	 in	10%FBS	RPMI1640	 culturing	media,	after	which	they	were	treated	with	1%FBS	50uM	BSA,	100uM	BSA	or	400uM	Palm	conjugated	 to	 BSA	 in	 a	 4:1	 ratio.	 100uM	 Oleate	 was	 conjugated	 directly	 to	 FBS.	
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Treatment	time	was	16h.	Cells	were	fixed	with	4%PFA	for	15min	and	stained	with	Hoechst	and	BODIPY493	 for	15min	and	subsequently	washed	 twice	with	PBS	and	imaged	 using	 the	 Operetta	 imager.	 Bodipy493	 Excitation	 460-490,	 Emission	 500-550,	Hoescht	Ex360-400	Em410-480.	
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Figure 3.5. Oleate GLT Model-Lipotoxicity Increases Basal Insulin Secretion 
and Impairs GSIS 
INS1	 cells	 were	 cultured	 in	 4mM	 glucose	 RPMI	 for	 at	 least	 2	 weeks.	 Cells	 were	plated	 in	 96-well	 plates	 and	 grown	 to	 70%	 confluence.	 Titration	 of	 Oleate	complexed	directly	 to	BSA	 in	 FBS	was	performed	 for	 a	 treatment	 time	of	 16-20h.	LT=	Lipotoxicity	(100uM	or	150uM	Oleate,	4mM	glucose).	GT=Glucotoxicity,	11mM	glucose.	 GLT=Glucolipotoxicity	 (100uM	 or	 150uM	 Oleate,	 11mM	 glucose).	 For	insulin	 secretion	assay,	 cells	were	pre-incubated	 in	2mM	RPMI	 for	2h	after	which	
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secretion	 assay	was	 performed	 in	 Krebs	 as	 described	 in	methods.	 A-D,	 n=3.	 A,	 B,	data	 normalized	 to	 ng	 of	 insulin	 per	 million	 cells	 per	 hour.	 C,	 D	 same	 data	normalized	as	percentage	of	insulin	content.	
 
 
 
 
 
 
 
 
 
 
 
 
 	61	
CHAPTER FOUR: Cyclophilin D-dependent Mitochondrial Proton Leak 
Regulates Insulin Secretion at Basal Glucose 
 
Nour Alsabeeh1,2,3*, Evan P. Taddeo1*, Jakob D. Wikstrom4, Samuel B Sereda4, 
Eleni Ritou1, Linsey Stiles1, Richard Kibbey5, Marc Liesa1, Orian S. Shirihai1, 4 
 
1Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, 
UCLA David Geffen School of Medicine, Los Angeles, California 90095, USA 
2Department of Physiology and Biophysics, Boston University School of 
Medicine, Boston, Massachusetts 02118, USA  
3Department of Physiology, Faculty of Medicine, Kuwait University, Kuwait 
4Department of Medicine, Boston University School of Medicine, Boston, 
Massachusetts 02118, USA, 5Cellular and Molecular Physiology, Yale University, 
New Haven, CT 06520, USA  
*Authors contributed equally and are listed in alphabetical order  
 
 
 	62	
Introduction 
 Mitochondria are essential to pancreatic beta cell function (Maechler & 
Wollheim, 2001), as they are fuel integrators and generators of multiple signals 
such as ATP, ROS, GTP, and NADPH for insulin secretion (Wiederkehr & 
Wollheim, 2012) (Prentki, Matschinsky, & Madiraju, 2013). Beta-cell mitochondria 
are characterized by an inherently high level of bioenergetic inefficiency, since 
they display a high level of proton leak as compared to other cell types (Wikstrom 
et al., 2012). Leak represents the fraction of oxygen consumption that does not 
result in ATP production, but generates heat by dissipation of the proton motive 
force. Leak may occur in the basal state, and is a function of mitochondrial 
membrane potential and ATP/ADP ratio(Nicholls, 2016). Thus, under conditions 
of nutrient excess, the proportion of leak is augmented since metabolism of 
nutrients increases membrane potential and the ATP/ADP ratio (Liesa & Shirihai, 
2013; Nicholls, 2016). These observations were first shown in isolated 
mitochondria derived from the clonal rat insulinoma cell line INS1 by the Brand 
lab(Affourtit & Brand, 2006), and subsequently confirmed by our group in primary 
mouse and human islets (Wikstrom et al., 2012). 
Uncoupling reduces the bioenergetic efficiency of ATP production, which 
may contribute to the impairment of GSIS. Uncoupling protein 2 (UCP2) was 
proposed to mediate the beta cell proton leak. Initial data from whole body mixed 
background UCP2 KO mice revealed improved insulin secretory capacity, 
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improved glucose tolerance, and higher ATP and ROS levels(Joseph et al., 
2004; S. C. Lee, Robson-Doucette, & Wheeler, 2009; C.-Y. Zhang et al., 2001). 
However, this was contradictory to data from UCP2 KO mice in a congenic 
background, where a normoglycemic phenotype with reduced insulin secretion 
and higher ROS production was observed (Pi et al., 2009). Convincing evidence 
opposing UCP2 as the source of the high leak in beta cells emerged from a beta 
cell specific KO model. UCP2-/- islets displayed no difference in oligomycin-
insensitive respiration (leak) as compared to controls, even though a higher basal 
oxygen consumption rate (OCR) was observed. These islets have a higher ROS-
dependent GSIS, with no effect on islet ATP content. While these mice are 
glucose intolerant, this was attributed to changes in alpha cell mass and 
dysregulation of glucose induced glucagon secretion as a result of increased islet 
ROS levels. Furthermore, this observation of reduced GSIS and increased 
oxidative stress was confirmed in 3 independent congenic UCP2 KO mouse 
strains (Pi et al., 2009) (Pi & Collins, 2010). As such, the mechanisms 
contributing to beta cell leak and how leak regulates beta cell insulin secretion is 
currently unknown.  
Islets exposed to excess nutrients display a higher mitochondrial proton 
leak (Carlsson et al., 1999), in addition to higher basal insulin secretion(Fex et 
al., 2007). We have previously suggested that acute induction of mitochondrial 
leak mediates production of signals for insulin secretion, while chronic exposure 
to excess nutrients may be detrimental to mitochondrial health and beta cell 
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function(Liesa & Shirihai, 2013). Herein, we explored the relationship between 
leak and insulin secretion. There are multiple factors that may contribute to 
proton leak such as pores, electrogenic pumps, channels, or exchangers. 
Previous studies have revealed a signaling role of ROS in mediating basal insulin 
secretion (Pi et al., 2007; Saadeh et al., 2012). An attractive target is the PTP, 
since evidence suggests a low-conductance physiological role for the PTP, and 
that the PTP has been shown to be modulated by ROS and fatty acids (Bernardi 
et al., 2015).We hypothesize that leak induces insulin secretion via nutrient 
regulation of ROS-induced opening of the PTP and that this may contribute to 
hyperinsulinemia of the pre-diabetic state. 
 
Results 
Mitochondrial Proton Leak Stimulates Basal Insulin Secretion in Islets 
 
Given the characteristically distinct and inherently high levels of proton 
leak in pancreatic beta cells, we sought to measure how proton leak may change 
in islets acutely exposed to various nutrients. To accomplish this, we employed 
our previously established high throughput method of intact islet respirometry to 
measure mitochondrial proton leak, which is the fraction of respiration that is 
independent of ATP-synthesis in cells with coupled mitochondria(Wikstrom et al., 
2012). To establish the resting energy demand, oxygen consumption was 
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measured in human islets in the presence of 3mM glucose (basal). The same 
islet preparations were subsequently exposed either to 3mM glucose, 20mM 
glucose (stimulatory), or 3mM glucose with 10mM Leucine/Glutamine (5mM of 
each amino acid). Islets were then treated with the ATP synthase inhibitor 
oligomycin A to enable measurement of ATP independent respiration. This 
represents the fraction of oxygen consumed independently of generating ATP, 
thereby reflecting a dissipation of proton motive force. Despite a low 
concentration of glucose, the amino acids Leucine/Glutamine induced a similar 
amount of leak compared to stimulatory glucose levels (Figure 4.1A-B). To 
further understand how nutrient composition affects islet mitochondrial proton 
leak, mouse islets were exposed to either basal or stimulatory levels of glucose 
(3mM or 20mM respectively) with or without additions of 0.4mM palmitate or 
10mM leucine/glutamine. Figure 4.1C, indicates that amino acids under basal 
glucose levels have the highest level of mitochondrial proton leak, irrespective of 
the glucose concentration, since the leak observed is similar to addition of amino 
acids under stimulatory levels of glucose.  We next sought to determine if nutrient 
regulation of proton leak correlated with nutrient stimulation of insulin secretion. 
Indeed, amino acids enhanced insulin secretion under both basal and stimulatory 
glucose levels. This led us to hypothesize that mitochondrial proton leak may 
promote/mediate insulin secretion. Remarkably, islets treated with the uncoupler 
dinitrophenol (DNP) displayed increased proton leak and increased insulin 
secretion under basal/low glucose levels (Supplementary Figure 4.1 A and B). 
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However, DNP may have an effect on insulin secretion independent of 
mitochondrial uncoupling via depolarization of the plasma membrane. Therefore, 
an uncoupler, BAM15, which does not depolarize the plasma membrane 
(Kenwood et al., 2014) , was utilized to confirm this observation is a result of 
mitochondrial uncoupling. Indeed, Figures 4.1E and 4.1F show the increased 
proton leak and increased insulin secretion of mouse islets upon exposure to 
1uM BAM15 in basal glucose. 
 
Reactive Oxygen species Increase Mitochondrial Proton Leak and Basal Insulin 
Secretion in Islets 
 
While chronic excess ROS/oxidative stress are known to have damaging 
effects on beta cell function (Oprescu et al., 2007), ROS have also been 
implicated as a signal for insulin secretion (Pi et al., 2007; Saadeh et al., 2012). 
Since we have established that mitochondrial proton leak stimulates insulin 
secretion, our next objective was to elucidate the relationship between ROS and 
proton leak. We first wanted to determine changes in ROS production upon 
nutrient treatment. Since the combination of the amino acids Leucine/Glutamine 
promoted the largest increase in leak (Figure 4.1 C), these nutrients were 
selected to determine changes in ROS. We hypothesized that nutrient-induced 
ROS production mediates leak and insulin secretion. The fluorescent probe, 
DCFDA, which assesses reactive oxygen and nitrogen species (Kalyanaraman et 
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al., 2012), was utilized to measure differences in the redox state of mouse islets 
treated with basal 3mM glucose or 10mM Leu/Gln in addition to 3mM glucose 
with or without the antioxidant MnTBAP. Figure 4.2A indicates an increase in 
ROS upon incubation with amino acids that is abrogated upon co-incubation of 
MnTBAP. This result corresponded with a decrease of mitochondrial proton leak 
as seen in Figure 4.2B. This suggests ROS are necessary to promote nutrient 
induced changes in proton leak. To further strengthen these findings, we 
performed a gain of function experiment. Incubation of islets in hydrogen 
peroxide induced insulin secretion at basal glucose levels (Fig 4.2C). To 
determine the effect of increased ROS on leak, the pro-oxidant, menadione was 
employed to determine if ROS would induce leak as seen in Fig 4.2D. 
Menadione consumes NADPH via redox cycling, thereby reducing the 
antioxidant ability of glutathione (Criddle et al., 2006). Addition of the antioxidant 
MnTBAP did not significantly change BAM15-stimulated insulin secretion (Fig 
4.2E), suggesting that ROS is upstream of proton leak. 
 
Amino-acid and Fatty Acid Stimulation of Insulin Secretion at Basal Glucose is ROS-
dependent. 
 
Our data suggest that ROS stimulate insulin secretion and proton leak 
under basal glucose, and that ROS is upstream of leak. Given that amino acid 
induced leak is ROS dependent, we hypothesized that amino acid induced 
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insulin secretion at low (basal) glucose is contingent upon an increase in ROS. 
To test this, mouse islets were incubated in basal glucose with addition of amino 
acids in the presence or absence of MnTBAP. MnTBAP significantly decreased 
the amino acid effect on insulin secretion. This confirms that the effect of acute 
treatment of amino acid induced insulin secretion is ROS-dependent. 
Furthermore, to determine if the increase in ROS is necessary for other nutrient 
induced insulin secretion under basal glucose levels, we tested the effect of a 
combination of saturated and unsaturated fatty acids, oleate/palmitate. While 
fatty acids were shown to increase leak (Fig 4.1C) and insulin secretion (Fig 
4.1D), we observed a trend toward a decrease in basal secretion in the presence 
of oleate/palmitate upon treatment with the antioxidant EUK (Fig 4.3B).  EUK 
reduction of basal insulin secretion with oleate/palmitate was only performed in 
two independent experiments. This result perhaps suggests separate 
mechanisms by which amino acids and fatty acids induce basal insulin secretion 
(under low/basal glucose conditions), since treatment with antioxidants had a 
much greater response in insulin secretion stimulated by amino acids. 
 
The Mitochondrial Permeability Transition Pore Regulates Proton Leak and Insulin 
Secretion in Islets 
 
We have established that mitochondrial leak is sufficient to induce insulin 
secretion and that ROS mediates this effect of leak on secretion in a nutrient 
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dependent manner. The key outstanding question was to determine the source of 
the leak. It has previously been established that the mitochondrial permeability 
transition pore can also function in a physiological low conductance state that is 
separate from its high-conductance state that initiates cell death (Ichas & Mazat, 
1998; Yehuda-Shnaidman, Kalderon, Azazmeh, & Bar-Tana, 2010). Indeed, the 
PTP can be activated by ROS or by FFA (Bernardi et al., 2015). While the overall 
structure and components of the mPTP are still debated in the field, a key 
established regulator of the PTP is Cylophilin D, a peptidyl prolyl cis-trans 
isomerase located in the mitochondrial matrix (Giorgio et al., 2017). The absence 
of CypD increases the threshold required of calcium to induce PTP opening, 
maintaining the PTP in a closed state (Basso et al., 2005). Cyclophilin D 
expression is shown to increase with aging (Moreno-Asso, Castaño, Grilli, 
Novials, & Servitja, 2013) and evidence indicates an increase of Cyclophilin D 
expression in diabetic islets as compared to non-diabetic controls (Taneera et al., 
2012) (Taneera et al., 2013) (Kanatsuna et al., 2013). Hence, we hypothesized 
that PTP could be the source of the leak. To determine if the PTP contributes to 
the leak, NIM811, a cyclosporine derivative that is an inhibitor of cyclophilins, 
was used (Waldmeier, Feldtrauer, Qian, & Lemasters, 2002). NIM811 is an 
alternative to CsA, which avoids the off-target effects of inhibiting calcineurin and 
therefore does not possess immunosuppressive effects. Pharmacological 
inhibition of CypD with Nim811 significantly reduced amino acid 
(Leucine/Glutamine)-induced proton leak and insulin secretion (Fig 4.3A and Fig 
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4.3B). To test if this phenomenon was nutrient specific, we determined if NIM811 
had a similar effect on fatty acids, since they are known to induce PTP opening. 
To do so, a combination of oleate and palmitate, complexed to BSA in FBS, was 
used to stimulate insulin secretion and leak with or without addition of the PTP 
inhibitor NIM811. NIM811 also prevented the FA induced increase on insulin 
secretion and leak (Fig 4.3C and Fig 4.3D).  
 
Role of Cyclophilin D on Leak, Basal and Glucose Stimulated Insulin Secretion 
 
Given that pharmacological approaches have a higher risk of off-target 
effects, a genetic approach was applied to determine the effects of cyclophilin D 
ablation in beta cell leak and secretion. Deletion of CypD is a validated model for 
inhibition of PTP opening, as it necessitates a higher calcium threshold to 
activate the PTP (Basso et al., 2005). Islets were isolated from whole body 
Cyclophilin D KO C57BL6J mice at 12 weeks. The profile of these islets was 
characterized ex vivo under basal and stimulatory glucose levels. KO islets and 
corresponding WT littermate control islets were incubated in either basal 3mM 
glucose, or stimulatory 20mM glucose to measure leak or insulin secretion in 
independent experiments. CypD deficient islets displayed lowered proton leak 
revealed by oligomycin insensitive respiration, and insulin secretion under low 
glucose conditions, while no significant difference was observed under 
stimulatory levels (GSIS). (Fig. 4.5A, 4.5B and Supplementary Fig 4.2A,B).  
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The mitochondrial permeability transition pore regulates proton leak and insulin 
secretion in islets from high fat-fed mice 
 
Exposure of islets to excess nutrients impairs beta cell function in a time 
dependent manner (Paolisso, Gambardella, et al., 1995a; Sako & Grill, 1990). 
Since it has been shown that pre-diabetic islets from obese mice have increased 
gene expression of CypD and increased basal secretion (Taneera et al., 2012) 
(Taneera et al., 2013) (Kanatsuna et al., 2013), we hypothesized that islets from 
high fat diet (HFD) fed mice would reveal higher protein expression of CypD. Fig 
4.6A and B, show that islets obtained from mice fed a HFD (60% fat, 12weeks) 
have higher expression of CypD. Indeed, these islets display basal insulin 
secretion and proton leak that is sensitive to pharmacological inhibition of CypD 
by NIM811 (Fig.4.6 C,D), suggesting that increased CypD dependent leak may 
be contributing to basal hyperinsulinemia. 
 
Proton leak induced insulin secretion requires generation of mitochondrial GTP 
 
It is intriguing that mild mitochondrial uncoupling amplifies basal and 
nutrient stimulated insulin secretion. This suggests that leak enables generation 
of a signal that may amplify insulin secretion. Mild uncoupling will likely lead to 
increased TCA cycle flux to generate the same amount of ATP. In previous 
studies, the Kibbey lab has shown that mitochondrial GTP generation is a signal 
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modulating insulin secretion (Kibbey et al., 2007). This observation came from 
comparison of the roles of two isoforms of the TCA cycle enzyme, Succinyl-CoA 
Synthetase. While both isoforms metabolize the same substrate, one produces 
GTP (SCS-GTP) while the other produces ATP (SCS-ATP) as a byproduct. The 
mitochondrial GTP isoform has been shown to amplify insulin secretion via 
increased PEP cycling and serves as an indicator for TCA cycle flux (Fig. 4.7A, 
Supplementary Fig. 4.3). Mitochondrial PEPCK utilizes mGTP to convert 
oxaloacetate to PEP, which is exported from the mitochondria and converted to 
pyruvate via pyruvate kinase (PK) (Stark & Kibbey, 2014; Stark et al., 2009). It is 
mechanistically unclear how mitochondrial derived PEP amplifies insulin 
secretion (Stark & Kibbey, 2014). We hypothesized leak increases TCA cycle flux 
and concomitantly increases mGTP production. To answer this question, INS1 
cells expressing the ATP isoform of succinyl CoA synthetase (hSCS-ATP) at a 
much higher ratio when compared to SCS-GTP (inhibition of SCS-GTP by 
competition), or control cells, which express equally both the ATP and GTP 
isoforms of SCS were treated with BAM15 under basal 2mM glucose conditions. 
BAM15 significantly stimulated insulin secretion in the control INS1 cells as 
compared to the hSCS-ATP cells, indicating that proton leak stimulated insulin 
secretion requires the generation of mitochondrial GTP (Fig 4.7B). To determine 
if this is also the mechanism by which leak regulated insulin secretion in an acute 
or chronic excess nutrient condition, INS1 cells expressing either the ATP or 
GTP isoforms of SCS were acutely treated with the amino acids Leu/Gln (45 min) 
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or with 150uM oleate (48h), after which insulin secretion was assayed. Figure 
4.7C indicates that amino acids acutely increase basal insulin secretion (glucose 
2mM) in INS1 cells in a manner that requires generation of mitochondrial GTP. 
Figure 4.7D indicates that chronic oleate treatment does not increase basal 
insulin in INS1 expressing hSCS-ATP isoform, while there is a 2-fold increase in 
the hSCS-GTP isoform. Thus, this result suggests that SCS-GTP activity might 
be required for excess fatty acids to increase basal secretion. 
 
Discussion 
 While the majority of beta cell research focuses on mechanisms of 
stimulating GSIS, our study reveals a novel bioenergetic mechanism that 
regulates basal insulin secretion (under low glucose). These findings provide an 
innovative means by which a potential therapeutic target for hyperinsulinemia of 
the pre-diabetic state may be developed. This mechanism promotes insulin 
secretion under low glucose conditions upon both acute and chronic exposure to 
excess nutrients. We have shown that increased mitochondrial leak acutely 
increases insulin secretion, while chronic exposure of islets to excess nutrients 
results in leak that leads to decreased bioenergetic efficiency. While previous 
studies have proposed that leak may be contributed by UCP2 or the ANT, no 
convincing evidence has been demonstrated in beta cells (Nicholls, 2016). Our 
investigation on the role of mitochondrial proton leak on beta cell function has 
revealed that leak stimulation of insulin secretion is mediated by the PTP and 
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that this pathway is dependent upon ROS or physiological mixtures of fatty acids 
oleate and palmitate. 
We have shown that acute treatment of islets with fatty acids stimulates 
basal insulin secretion and increased mitochondrial leak. We also show that leak 
itself, via addition of a specific mitochondrial uncoupler, is sufficient to stimulate 
insulin secretion at basal glucose levels. This suggests that the increase in leak 
promotes the production of additional mitochondrial signals that amplify insulin 
secretion signaling. We determined that leak stimulates insulin secretion via 
increased GTP generation by the TCA cycle, as our experiments in which the 
different isoforms of SCS were manipulated to generate either ATP, GTP or both, 
revealed that leak induction of insulin secretion requires generation of 
mitochondrial GTP. 
Previous studies have implicated a signaling role for ROS in insulin 
secretion (Pi et al., 2007; Saadeh et al., 2012). Here, we reveal that acute amino 
acid treatment increases insulin secretion in a ROS-dependent manner, as 
treatment with MnTBAP reduces the amino acid stimulated increases in insulin 
secretion. Most importantly, we identify the PTP as the source of the nutrient 
induced leak, as addition of the CypD inhibitor, NIM811 reduces Leu/Gln and 
Oleate/Palmitate insulin secretion and leak. 
Our working model places ROS upstream of the leak for amino acids, 
since addition of MnTBAP did not reduce BAM15 mediated insulin secretion. 
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Further studies may be needed to differentiate ROS scavenging or uncoupling for 
non-specific drug effects. It is noteworthy to mention that amino acids potently 
induce secretion as compared to fatty acids, while they maintain similar 
increases on proton leak. This may be due to the dose of nutrients utilized or 
other effects of the amino acids leucine and glutamine. In addition to being 
metabolized and activating TCA cycle activity, the increased secretion may result 
from direct effects of leucine/amino acid-derived metabolites on the plasma 
membrane KATP channel (Newsholme, Bender, Kiely, & Brennan, 2007). 
Furthermore, EUK did not appear to have a strong inhibitory effect on fatty acid 
induced insulin secretion. This suggests the possibility that the mechanism by 
which leak is induced is nutrient dependent. Whereby amino acids may increase 
leak via increased TCA cycle flux and consequent ROS generation, fatty acids 
may induce leak by directly activating the PTP in an acute setting. However, in a 
chronic setting, increased generation of mitochondrial GTP is required for fatty 
acids to increase basal insulin secretion. 
 
We have shown that increased leak observed in islets from HFD animals 
is sensitive to NIM811, supporting the hypothesis that increased CypD 
expression in diabetic islets (Taneera et al., 2012) (Taneera et al., 2013) 
(Kanatsuna et al., 2013) may be contributing to increased basal insulin secretion 
and hyperinsulinemia. Future studies will be necessary to test whether beta cell 
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specific ablation of CypD is protective under HFD, as this would enable 
identification of a therapeutic target to prevent hyperinsulinemia in the pre-
diabetic state. 
 	77	
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Figure 4.1. Mitochondrial Proton Leak Stimulates Basal Insulin Secretion in 
Islets.  
	(A)	 Representative	 traces	 showing	 absolute	 values	 of	 human	 islet	 oxygen	consumption.	Basal	respiration	was	measured	over	time,	and	changes	in	respiration	were	assessed	after	sequential	addition	of	different	nutrients	and	the	mitochondrial	ATP	 synthase	 inhibitor	 oligomycin	 to	 calculate	 mitochondrial	 proton	 leak.	 Islets	were	 incubated	 in	 3mM	 glucose	 and	 then	 injected	with	media	with	 3mM	 glucose	(red	trace),	20mM	glucose	(blue	trace)	or	10mM	leucine	+	glutamine	(5mM	of	each	amino	 acid,	 green	 trace).	 (B)	 Mitochondrial	 proton	 leak	 of	 human	 islets	 after	addition	of	3mM	glucose,	20mM	glucose	or	10mM	leucine	+	glutamine.	Proton	leak	is	expressed	as	the	oligomycin	insensitive	respiration	normalized	as	a	percentage	of	basal	respiration.	n	=	4-10	donors.	(C)	Mitochondrial	proton	leak	from	mouse	islets	exposed	 to	 either	 3mM	 or	 20mM	 glucose,	 in	 the	 absence	 or	 presence	 of	 400µM	palmitate	 conjugated	 to	 BSA	 or	 10mM	 leucine	 +	 glutamine.	 n=4	 independent	experiments,	each	containing	islets	pooled	from	8	mice	fed	a	chow	diet.	(D)	Insulin	secretion	from	mouse	islets	incubated	in	either	3	or	16.7mM	glucose	in	the	absence	or	presence	of	10mM	leucine	+	glutamine	or	90µM	fatty	acids	(60µM	oleate/30µM	palmitate	complexed	to	FBS)	or	FBS	control.	n	=	6-10	independent	experiments.	(E)	Mitochondrial	 proton	 leak	 in	 mouse	 islets	 treated	 with	 1µM	 of	 the	 uncoupler	BAM15.	n	=	3	independent	experiments.	(F)	Basal	insulin	secretion	in	3mM	glucose	
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Krebs	 from	BAM15-treated	mouse	 islets.	 n	 =	5	 independent	 experiments.	All	 data	are	means	±	standard	error	of	the	mean	(SEM).	For	B,	**	indicates	p<0.001	obtained	with	 Student	 t	 test	 when	 compared	 to	 3	mM	 glucose	 injection.	 For	 C,	 E	 and	 F,	 *	indicates	p<0.05	in	a	Student	t-test.		
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Figure 4.2. Reactive Oxygen Species Increase Mitochondrial Proton Leak 
and Basal Insulin Secretion in Islets. 
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(A)	 Reactive	 oxygen	 species	 (ROS)	 were	 measured	 in	 dispersed	 islet	 cells	 after	staining	with	10µM	CM-H2DCFDA	for	one	hour	and	incubation	with	3	mM	glucose	in	the	absence	or	presence	of	10mM	leucine/glutamine	and	20µM	MnTBAP	for	15min.	n	=	4	 independent	 experiments.	 (B)	Mitochondrial	 proton	 leak	 from	 islets	 acutely	exposed		to	3mM	glucose	or	10mM	leucine/glutamine	in	the	absence	or	presence	of	20µM	 TBAP.	 n	 =	 4	 independent	 experiments.(C)	 Insulin	 secretion	 from	 islets	incubated	 in	 3mM	 glucose	 Krebs	 buffer,	 or	 3mM	 Glucose	 Krebs	 buffer	 in	 the	presence	 of	 500uM	 H2O2	 with	 or	 without	 addition	 of	 NAC.	 n=	 3-5	 independent	experiments,	p<0.05	compared	to	vehicle	(*)	or	H2O2	(#)	by	one-way	ANOVA.	(D)	Mitochondrial	 proton	 leak	 measured	 in	 islets	 treated	 with	 the	 ROS-generating	compound	 menadione	 (10µM)	 or	 DMSO	 vehicle.	 Islets	 were	 incubated	 with	menadione	 for	 30	 minutes	 prior	 the	 start	 of	 respirometry.	 n	 =	 4	 independent	experiments.	 (E)	 Insulin	 secretion	 from	 islets	 incubated	 in	 3mM	 glucose	 Krebs	buffer	 in	 the	 absence	 or	 presence	 of	 1µM	 BAM15	 or	 20µM	 TBAP.	 Islets	 were	exposed	to	compounds	for	45	min,	during	the	secretion	period.	n	=	7-8	independent	experiments.	All	data	are	means	±	SEM..		For	A,	**	indicates	p<0.001	Student	t-test.	For	B,	 *	 indicates	p<0.05;	 **	 indicates	p<0.001	of	Student	 t-test.	For	D,	 *	 indicates	p<0.05		Student	t-test.		
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Figure 4.3. Amino-acid and Fatty Acid Stimulation of Insulin Secretion at 
Basal Glucose is ROS-dependent.  
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(A)	Amino	acid-induced	insulin	secretion	in	3mM	glucose	from	mouse	islets	treated	with	20µM	MnTBAP	(10mM	leucine/glutamine).	n	=	3-4	independent	experiments,	p<0.05	compared	to	vehicle	(*)	or	Leu/Gln	(#)	by	one-way	ANOVA	(B)	Fatty	acid-induced	insulin	secretion	in	3mM	glucose	from	mouse	islets	treated	with	EUK-207	(Oleate/Palmitate	150uM,	2:1	ratio,	total	225uM).	n=2	
  
 	84	
 
 
Figure 4.4. The Mitochondrial Permeability Transition Pore Regulates 
Proton Leak and Insulin Secretion in Islets.   
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(A)	Mitochondrial	proton	leak	in	islets	acutely	exposed	to	10mM	leucine/glutamine	(Leu/Gln)	in	the	absence	or	presence	of	the	cyclophilin	D	(CypD)	inhibitor	NIM811.	Islets	 were	 treated	 with	 DMSO	 vehicle	 or	 1µM	 NIM811	 in	 Seahorse	 media	containing	 3mM	 glucose	 for	 1hr	 prior	 to	 respirometry.	 n	 =	 4	 independent	experiments.	 (B)	 Insulin	 secretion	 from	 islets	 incubated	 with	 10mM	 LG	 in	 3mM	glucose	in	the	absence	or	presence	of	1µM	NIM811.	Islets	were	exposed	to	NIM811	during	both	 the	30min	pre-incubation	and	45	min	secretion	periods,	 for	a	 total	of	75min.	n	=	4-5	independent	experiments.	(C)	Insulin	secretion	from	islets	incubated	with	225uM	fatty	acids	 (150uM	oleate/75uM	palmitate)	conjugated	 to	FBS	or	FBS	control	 diluted	 in	 3mM	glucose	Krebs	 buffer.	 Islets	were	 incubated	with	 the	 fatty	acids	 for	 the	 45min	 secretion	 period.	 n	 =	 3	 independent	 experiments.	 (D)	Mitochondrial	proton	leak	in	 islets	acutely	treated	with	225uM	fatty	acids	(150uM	oleate/75uM	 palmitate).	 n=1.	 For	 A-B,	 significant	 difference	 compared	 to	 DMSO	control	 (*)	 or	 10mM	 LG	 (#)	 by	 one-way	 ANOVA.	 For	 C,	 significant	 difference	compared	 to	 FBS	 control	 (*)	 or	 OP	 (#)	 by	 one-way	 ANOVA.	 	 OCR,	 Oxygen	Consumption	Rate.	 	
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Figure 4.5. Cyclophilin D Deficient Islets Display Lower Mitochondrial 
Proton Leak and Insulin Secretion at Basal Glucose 
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(A)	Basal	insulin	secretion	in	islets	isolated	from	CypD	KO	mice;	n=5	per	genotype	(B)	Mitochondrial	proton	leak	is	reduced	in	islets	from	CypD	KO	mice;	n=3	mice	per	group.	Error	bars	represent	±	SEM;	*,	p<0.05	by	Student’s	t	test.	
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Fig 4.6.  The Mitochondrial Permeability Transition Pore Regulates Proton 
Leak and Insulin Secretion in HFD Mouse Islets 
(A)	Western	blot	image	and	(B)	quantification	of	2	independent	islet	isolations	from	mice	fed	a	chow	or	HFD	(60%	kcal	from	fat	for	12	weeks);	n=2	mice	per	group.	(C)	NIM811	reduces	basal	insulin	secretion	in	3mM	glucose	in	islets	isolated	from	HFD	mice.	n=3,	Error	bars	represent	±	SEM;	*,	p<0.05	by	Student’s	t	test.	(D)	NIM811-
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sensitive	proton	leak	in	islets	from	chow-	or	HFD-fed	mice.	NIM811-sensitive	leak	was	calculated	by	subtracting	the	leak	in	the	presence	NIM811	from	the	average	respective	DMSO	control	leak	value,	dividing	this	value	by	the	DMSO	control	leak	and	multiplying	by	100.	n	=	3	(Chow)	or	4	(HFD)	independent	experiments.	p	=	0.08	by	two-tailed,	unpaired	t-test.	
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Figure 4.7. Proton leak induced insulin secretion requires generation of 
mitochondrial GTP  
(A)	 Schematic	 displaying	 PEP	 cycling	 links	mGTP	 production	 to	 insulin	 secretion.	(Stark,	 Kibbey	 PMID:19635791)	 Since	 GTP	 cannot	 exit	 mitochondria,	 PEPCK	converts	oxaloacetate	and	GTP	into	PEP	and	GDP.	GDP	is	recycled	by	SCS-GTP	while	PEP	 is	 exported	 from	 the	 mitochondria	 and	 has	 been	 shown	 to	 increase	 insulin	secretion.	 The	 mechanism	 by	 which	 this	 occurs	 remains	 unclear.	 Increased	production	of	PEP	resulting	from	overexpression	of	the	SCS-GTP	isoform	results	in	greater	insulin	secretion.	The	SCS-ATP	isoform	does	not	contribute	to	increased	PEP	production	 or	 export	 from	mitochondria	 resulting	 in	 lower	 insulin	 secretion.	 (B)	INS1	cells	expressing	hSCS-ATP	have	reduced	basal	insulin	secretion	in	response	to	mitochondrial	 uncoupler	 BAM15.	 n=3,	 ,	 p<0.05	 by	 two	 way	 ANOVA	 compared	 to	DMSO	control.	(C)	Acute	amino	acid	data	in	ATP/GTP	cells.	n=4	p<0.05	compared	to	INS1	 control	 2mM	 glucose	 +	 Leu/Gln	 by	 two	 way	 ANOVA.	 (D)	 Chronic	 Oleate	treatment	does	not	 increase	basal	 insulin	 secretion	 in	 INS1	cells	 expressing	hSCS-ATP	isoform.	n=2		
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Figure 4.8. Mechanism of Elevated Insulin Secretion at Basal Glucose 
Concentrations.  
Increase	 in	 insulin	 secretion	 at	 basal	 glucose	 concentrations	 is	 the	 result	 of	uncoupling	 mediated	 by	 a	 proton	 leak	 through	 the	 Permeability	 Transition	 Pore	(PTP).	In	the	obese	state,	the	PTP	becomes	activated	due	to	increased	expression	of	the	PTP	activator,	CyPhD.	CyPhD	increases	the	PTP	sensitivity	to	Ca2+,	ROS	and	FAs.	Proton	leak	through	the	PTP	consumes	NADH	and	increases	the	flux	in	the	TCA	cycle	as	 the	 mitochondria	 attempt	 to	 maintain	 membrane	 potential,	 which	 in	 turns	generates	 GTP.	 Mitochondrial	 GTP	 amplifies	 phosphoenolpyruvate	 production,	which	is	a	coupling	factor	for	insulin	secretion.															
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Supplementary Figure 4.1. Mitochondrial bioenergetics and insulin 
secretion in mouse islets treated with uncouplers.  
	(A)	 Proton	 leak	 in	mouse	 islets	 acutely	 exposed	 to	 10µM	 dinitrophenol	 (DNP)	 or	DMSO	vehicle.	n	=1	independent	experiment.	(B)	Insulin	secretion	from	mouse	islets	
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incubated	 with	 DNP	 or	 DMSO	 for	 30min	 in	 3mM	 glucose.	 n	 =	 3	 independent	experiments.	Data	are	means	±	SEM.	*p	<	0.05	by	unpaired,	two-tailed	t-test.								
 	96	
		
 
Supplementary Figure 4.2. Ablation of CypD does not reduce insulin 
secretion or leak under stimulatory glucose levels.  
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(A)	GSIS	in	CyPhD	KO	islets	is	not	significantly	reduced;	n=3.	Error	bars	represent	±	SEM;	*,	p<0.05	by	Student’s	t	test.	(B)	Mitochondrial	proton	leak	under	stimulatory	glucose	in	CypD	vs	WT	islets.	n=2	mice	per	genotype.												
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Supplementary Figure 4.3. Mitchondrial GTP increases both basal and 
glucose stimulated insulin secretion.  
	(A)	Transient	overexpression	of	the	ATP	and	GTP	isoforms	of	SCS	reduces	and	increases	LGIS	in	INS1	cells,	respectively;	n=6	*p<0.05										
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CHAPTER FIVE: General Discussion 
 
T2D is a multifactorial metabolic disease characterized by insulin 
resistance, impaired beta cell function, and hyperglycemia. The conventional 
model of T2D progression argues that insulin resistance of the peripheral tissues 
drives the hypersecretion of insulin from beta cells as a compensatory 
mechanism. This increased beta cell workload ultimately impairs beta cell 
capacity to secrete insulin due to beta cell exhaustion and eventual failure. 
However, an alternative theory provides compelling evidence supporting the 
hypothesis that hyperinsulinemia may be the primary defect which prompts 
changes in insulin sensitivity (Corkey, 2012b). In this case, the development of 
insulin resistance may be a compensatory response to avoid hypoglycemia, in 
addition to increased adiposity and negative effects of insulin signaling in other 
tissues (Erion & Corkey, 2017). Genome wide association studies indicate that 
majority of T2D risk genes reflect beta cell dysfunction (Florez, 2008). The only 
current treatments that restore beta cell function, secretory capacity, and 
response to glucose are fasting and bariatric surgery(Lim et al., 2011; Reed et 
al., 2011). Here, hyperinsulinemia is normalized independent of and prior to 
changes in insulin resistance. Furthermore, elimination of the beta cell insulin 
gene is protective from diet induced obesity (Mehran et al., 2012). Elucidating the 
cellular mechanisms that regulate basal insulin secretion and beta cell function, 
would allow us to test the role of hyperinsulinemia in the development of diabetes 
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and potentially identify therapeutic targets that may prevent or delay progression 
to T2D. In this thesis, I have developed an in vitro model of excess nutrients, and 
outline important parameters of glucolipotoxicity that must be considered. I have 
also identified a mechanism by which changes in beta cell bioenergetic function 
as it relates to PTP-mediated leak regulates beta cell insulin secretion in the 
basal state. 
 
 
Glucolipotoxicty: Challenges, Considerations, and Implications for β-cell Function 
 
In Chapter 3, I demonstrate the difficulties encountered when developing a 
protocol for a nutrient excess model. I also highlight the important factors that 
must be considered for technical reasons, as well as physiological implications 
for beta cell function. These findings resulted in a publication reviewing the 
problems encountered and solutions developed amongst our group and Prof 
Kowaltowski’s group (Alsabeeh, Chausse, Kakimoto, Kowaltowski, & Shirihai, 
2018). Excessive levels of circulating fatty acids observed in obesity are thought 
to deteriorate beta cell function, but exactly how fatty acids can change beta cell 
function is not well understood. Hence, in vitro development of glucolipotoxicity 
models allows for mechanistic insight on a cellular level. Fatty acids are insoluble 
in aqueous solutions, and are complexed to FA-free BSA, in a manner emulating 
the physiological or pathophysiological state.  
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The protocols by which fatty acids are complexed and applied for in vitro 
excess nutrient supplementation differ widely in the beta cell research field. A 
review of the literature displays variability of experimental design in the mode of 
FA supplementation regarding the percentage of serum in the media and addition 
of FA-free BSA in the controls. In some studies FA are dissolved in ethanol and 
directly added to culture media containing 10% FBS with an equivalent amount of 
ethanol to controls(Y. P. Zhou & Grill, 1994). Another study dissolves FA in 
DMSO, complexes to BSA, and added to media with 10%FBS, while the control 
media contains the equivalent FA-free BSA and DMSO(Maedler, Oberholzer, 
Bucher, Spinas, & Donath, 2003). Other studies reduce the percentage of FBS in 
the media (Las et al., 2011), while others are performed in serum free media 
(Karaskov et al., 2006). My results indicate that FA-free BSA causes a reduction 
in insulin secretion in a dose-dependent manner, while quantification of 
intracellular lipids shows reduction in lipid droplet content upon reduction of 
serum and addition of FA-free BSA. Although there is no empirical evidence to 
dissect the contribution of FBS reduction vs. addition of FA-free BSA, I speculate 
that the reduction in serum is likely to have a larger effect compared to addition 
of FA-free BSA in the controls. These factors are crucial to keep in mind, since 
FBS percentage in the media and/or addition of FA-free BSA in the controls may 
not only affect lipid content, but also likely sensitize the cells and influence other 
factors such as induction of autophagy in the case of a reduction in serum. The 
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mode of fatty acid preparation and administration must be considered to achieve 
robust experimental design.  
 
The ratio of FA:BSA is often not reported in the literature. This is an 
extremely important and overlooked aspect, since the ratio at which FAs are 
complexed to BSA dictates the fraction of bound/unbound free fatty acids, and 
determines the concentration of fatty acid the cells will be exposed to. This may 
create difficulty in interpretation of data from different labs in addition to the 
aspect of reproducibility from different FA preps. To circumvent this, confirmation 
via measurement of total FFAs or unbound FFAs may be valuable (Alsabeeh et 
al., 2018). 
 
β-cell Specific Physiological Considerations  
 
Traditionally, the INS1 pancreatic beta cell line is cultured in media 
containing 11mM glucose. Erion et al have shown that culturing these cells in 
high glucose or excess lipids results in a left-shifted response to GSIS, indicating 
they are more sensitized for insulin release at lower glucose concentrations 
(Erion et al., 2015). This potentially explains the phenomenon of basal 
hyperinsulinemia in the pre-diabetic obese state. Culturing INS1 cells in 4mM 
glucose, may require a longer growth time, but would reflect a right-shifted, more 
physiological condition under which there is a reduced intracellular lipid content 
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as seen in non-pathological islets. In addition to careful consideration for normal 
glucose culture conditions, studies of beta cells employing models of lipotoxicity 
or glucolipotoxicity in which only saturated fatty acids such as palmitate are 
supplemented are not physiological. It is important to note that a mixture of 
circulating saturated and unsaturated fatty acids exists in vivo. Moreover, 
palmitate is toxic to beta cells, contributing to formation of crystals and ER stress 
response, apoptosis, and inflammatory response (Busch et al., 2005; Karaskov 
et al., 2006). Oleate is protective from the negative effects of palmitate. Hence, 
the use of oleate or a combination of oleate and palmitate may be physiologically 
more accurate. 
 
Proton Leak Regulation of Insulin Secretion 
 
While it has been known for quite some time that beta cells have an 
inherently high level of proton leak (Affourtit and Brand 2008), it was unclear 
whether this leak plays a role in insulin secretion. Islets isolated from HFD mice 
have characteristically increased basal insulin secretion(Fex et al., 2007). Our 
data indicate that PTP mediated leak plays an important role in amplifying signals 
for insulin secretion under basal glucose, while perhaps serving as a 
detoxification system to protect beta cells from nutrient overload. Mitochondrial 
leak may result from various proteins, such as ion channels, and exchangers that 
may dissipate the membrane potential independently from ATP production. A 
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short list of putative candidates for mitochondrial proton leak includes UCP2, the 
ANT, NNT, and low conductance state PTP activity. In Chapter 4 we identify the 
PTP as a source of leak that contributes to signals for insulin secretion under low 
glucose. In the case of UCP2, it has already been reported in the literature that 
UCP2 beta cell specific KO islets do not have significant difference in leak as 
compared to their respective WT control islets under either basal or stimulatory 
levels of glucose (Robson-Doucette et al., 2011), ruling out the possibility that 
UCP2 contributes to proton leak.  
 
A limitation of our study is that we have not explored the contributions to 
leak from other candidates such as the ANT, which is responsible for ~50-67% of 
leak in the basal state of muscle mitochondria (M. D. Brand et al., 2005). ANT 
has a role in insulin secretion that is mediated by PEP, since PEP is inhibitory for 
ADP/ATP exchange (Ewart, Yousufzai, Bradford, & Shrago, 1983). Given that 
mitochondrial PEP export may be mediated by either the ANT or CIC 
(Passarella, Atlante, Valenti, & de Bari, 2003), future work determining the 
contribution of ANT to leak would be interesting to explore via bongrekic acid, an 
established ANT inhibitor (Klingenberg & Buchholz, 1973).  
 
The NNT, which consumes the membrane potential by generation of 
NADPH is likely another mechanism by which leak may occur. This is a limitation 
in our study, since our findings are obtained from islets isolated from the Jax labs 
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C57BL6J, which are NNT-deficient. A recent paper from Darrell Neufer’s group 
has compared the responses of two mouse strains of C57BL6J and C57BL6NJ 
which are NNT deficient or not, respectively (Fisher-Wellman et al., 2016). The 
NNT-deficient strain was hypothesized to display increased susceptibility to HFD, 
since the NNT is known to detoxify peroxides (Ronchi et al., 2013). However, no 
difference in susceptibility to HFD metabolic stress was observed. Moreover, the 
NNT-deficient strain displayed compensatory redox buffering capacity attributed 
to increased SOD2 and IDH2 (Fisher-Wellman et al., 2016). It would be 
interesting and valuable to test the contribution of PTP mediated leak in islets 
that express NNT as compared to our studies, since NNT is expressed in human 
islets. 
 
Role of Cyclophilin D in Metabolic Diseases 
 
Chapter 4 of this thesis reveals that diet induced obesity increases islet 
expression of CypD, and increases islet sensitivity to PTP mediated leak. 
Furthermore, islets from HFD mice have increased basal insulin secretion(Fex et 
al., 2007). Moreover, ablation of CypD reduces insulin secretion and 
mitochondrial leak under basal glucose without altering either at stimulatory 
glucose levels. These findings uncover a novel target to influence basal 
hypersecretion of insulin in the pre-diabetic state. Identification of this target 
(PTP) enables an alternative hypothesis in which prevention of hyperinsulinemia 
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may delay the associated changes in insulin resistance. A whole body KO of 
CypD is protective from diet-induced obesity, attributed to increased skeletal 
muscle glucose uptake (Taddeo et al., 2014). It is unclear if this is due primarily 
to improvement in insulin sensitivity or reduction in mitochondrial dysfunction. 
The possibility exists that a reduction in beta cell basal insulin secretion may play 
a role. Moreover, ablation of CypD in a PDX-1 deletion diabetes model prevents 
beta cell death, restores beta cell mass, and normalizes fasting blood glucose 
(Fujimoto, Chen, Polonsky, & Dorn, 2010). CypD KO or pharmacological 
inhibition of the PTP is also protective from hepatic steatosis (X. Wang et al., 
2018), further implicating the role of CypD in metabolic diseases. Future studies 
are needed to determine the contribution of CypD ablation on beta cell function 
and insulin sensitivity. It is noteworthy to mention that a study investigating the 
role for CypD on behavioral and neurological function uncovered a role for CypD 
in metabolism and energy expenditure upon observation of adult-onset obesity in 
KO mice. This was attributed to increased WAT and decreased locomotor activity 
(Luvisetto, Basso, Petronilli, Bernardi, & Forte, 2008). Understanding the 
discrepancies in these studies may lie in differences of the diet, age or gut micro 
biome and requires further work. 
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Pharmacological Implications of PTP Inhibition 
 
In Chapter 4 we also reveal the possibility that inhibition of the PTP may 
be a therapeutic target to prevent fasting hyperinsulinemia during pre-diabetes. 
Our studies employed the use of NIM-811, a non-immunosuppressive compound 
that is a cyclosporine derivative (Waldmeier et al., 2002). Cyclosporine A has 
been widely utilized as an immunosuppressive agent for patients that undergo 
transplantation for many years. Studies conducted in the 80’s discovered that 
CsA acutely inhibits GSIS in a dose dependent manner that is not reversible after 
washout in HIT cells and rat islets (Robertson, 1986). Chronic CsA treatment 
impairs islet proinsulin biosynthesis, and reduces GSIS and DNA 
synthesis(Andersson et al., 1984). While CsA displays negative effects on GSIS, 
we find that acute treatment of islets with its analog, NIM-811 reduces basal 
hypersecretion of insulin under stimulation with fatty acids or amino acids. The 
negative effects of CsA may be due to its inhibition of calcineurin, which does not 
occur with NIM-811. Inhibition of calcineurin prevents dephosphorylation of the 
mitochondrial fission protein dynamin related protein 1 (Drp1) at Serine 637, a 
requirement for Drp1 translocation to mitochondria to induce mitochondrial 
fragmentation (Cereghetti et al., 2008). Prevention of mitochondrial fragmentation 
will result in inhibition of autophagy (Twig & Shirihai, 2011), which is critical for 
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mitochondrial quality control and beta cell function under pathophysiological 
conditions(Las et al., 2011). Nevertheless, it remains to be determined if 
inhibition of CypD with NIM-811 will have similar effects in islets exposed to 
chronic nutrient excess.  
 
Considerable attention has been dedicated to uncover various compounds 
for PTP inhibition, since protective effects are observed in many diseases and it 
has promising therapeutic potential (Šileikytė & Forte, 2016). NIM-811 displays 
anti-viral activities making it a therapeutic target for hepatitis B(Bouchard, Puro, 
Wang, & Schneider, 2003), hepatitis C (Ma et al., 2006), and HIV (Billich et al., 
1995; Rosenwirth et al., 1994). NIM-811 may also exert anti-inflammatory 
protective effects in a CypD independent manner, as recently shown in a model 
of encephalomyelitis (Huang, Pandya, Banta, Ansari, & Oh, 2017). Acute 
administration of NIM811 has also shown protective effects in animal models of 
traumatic brain injury (Readnower et al., 2011). Furthermore, NIM-811 and its 
analog Debio 025, have shown promising protective effects on mitochondrial 
function in multiple models of muscular dystrophy (Tiepolo et al., 2009) (Zulian et 
al., 2014). 
 
However, there are several challenges to the use of PTP inhibitors that 
target CypD (Šileikytė & Forte, 2016): 1) The essential structural components of 
the PTP and mechanism of opening have still not been resolved. 2) CypD is not 
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a core component of the pore, but a regulator; ablation of which serves to raise 
the calcium threshold at which PTP opening will occur. 3) Inhibitors of CypD are 
not only specific to CypD, but target all cyclophilins, making it difficult to ascertain 
whether the effects observed are due to PTP inhibition or involve other off target 
effects. 4) Other physiological functions of CypD have yet to be fully discovered 
(Javadov, Jang, Parodi-Rullán, Khuchua, & Kuznetsov, 2017). CypD does not 
serve solely as a regulator of the PTP, but also plays an important role in protein 
folding since it serves as a chaperone catalyzing isomerization of cis-trans 
peptidyl-prolyl bonds (P. Wang & Heitman, 2005). More recently, CypD has been 
shown to interact with mitochondrial transcription factors and influence 
expression of electron transport chain components such as NADH 
Dehydrogenase (ND1), cytochrome oxidase 1(COX1), and ATP synthase subunit 
6 (ATP6) (Radhakrishnan, Bazarek, Chandran, & Gazmuri, 2015). Successful 
development of isoform specific inhibitors of cyclophilins (Daum et al., 2009), 
would be extremely valuable to prevent undesirable effects on functions of other 
cyclophilins which may be unfavorable. Future research employing the use of 
other CypD inhibitors, or inhibitors of the PTP which act independently of 
targeting CypD may be valuable to discern the differences. This may be 
challenging, however, since most high throughput screens for PTP inhibitors are 
conducted on isolated mitochondria, which require further validation on intact 
cells where permeability may be a concern (Šileikytė & Forte, 2016). Finally, the 
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use of these compounds may have entirely different effects on an organismal 
level, which needs to be tested. 
 
Conclusions and Future Directions 
 
The overarching objectives of this thesis were to probe mechanisms 
contributing to HI of the pre-diabetic state. Since there is no consensus on the 
primary defect (HI or IR) that drives progression of T2D, elucidating molecular 
mechanisms that govern insulin secretion in the basal state independently of 
GSIS would enable manipulation of these pathways to characterize their 
contributions. Current T2D therapies do not prevent progression of disease, but 
rather exhaust beta cell function ultimately resulting in beta cell failure, 
compelling patients to resort to exogenous insulin therapy. Careful consideration 
for models of beta cell glucolipotoxicity is necessary to achieve results that can 
be more physiologically extrapolated. Our discovery of the PTP as a novel 
regulator of basal insulin secretion enables the possibility to test 
hyperinsulinemia as a driver of the pre-diabetic state. Future studies further 
characterizing the role of the PTP in beta cell dysfunction has therapeutic 
potential, particularly since this mechanism is shown to be fundamental 
contributor to many diseases.	
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